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ABSTRACT
Nitric oxide therapies for local inhibition of platelets’ activation on blood-contacting
surfaces
by
Kagya Agyeman Amoako
Chair: Keith E Cook
Blood-contacting devices interact with blood during their function much like the
endothelium that modulates hemostasis. The surfaces of these devices however, lack
endothelial-like properties, and consequently, upon blood contact, activate clotting
factors to form clots. Systemic heparinization for inhibiting clot formation can cause
bleeding and surface coatings show insignificant benefits.
This research investigated nitric oxide (NO) production mimicry of the endothe-
lium on artificial lungs (ALs) and pediatric catheters. Their surfaces were functional-
ized either by (1) entrapping NO donors inside their bulk, (2) incorporating catalysts
to generate NO from NO-donors or (3) supplementing NO into sweep gas of artificial
lungs. Pediatric catheters functionalized with NO-donor thin coats using method 1
is limited by short NO release duration. Method 2 has not been applied to large
surface-area, low-flow devices like the AL.
In this work NO-generating silicone membranes were synthesized and character-
ized to determine the relationship between surface properties, NO flux, and blood
clotting time. These outcomes helped develop and optimize NO-generating gas-
xiv
exchange silicone fibers that represent the majority of ALs surface area. The first
NO-generating AL prototypes, using those fibers, were manufactured, incorporated
into NO-generating circuits and tested for their non-thrombogenicity. To test for
NO-release duration and non-thrombogenicity, catheters were fabricated to incorpo-
rate NO-donors inside their walls, characterized for NO flux and release duration by
chemiluminescence, and tested for patency using a thrombogenicity model in rabbits.
Methods 1-2 involve material modification using complicated and expensive chemical
formulations and/or manufacturing. Method 3 however, functionalizes ALs by only
adding NO into sweep gas. Decade-long anti-clotting testing using a wide range of NO
concentrations has been conducted without knowledge of what concentration yields
endothelial NO flux levels in the AL. This concentration was determined for the MC3
Biolung and the Terumo capiox rx25 ALs in vitro.
All these ideas have shown positive results in short-term studies, and each may
play a necessary role in inhibiting clot formation in future ALs. The suﬃciency
however, of each idea or of a combination for clot inhibition in long-term ALs remains
to be determined.
xv
CHAPTER I
INTRODUCTION
1.1 Motivations and Objectives
The biocompatibility of blood-contacting biomaterials are especially important as
no biomaterial in blood-contacting devices like gas-exchangers, catheters, stents, and
dialysis membranes adequately prevents clot formation without some form of sys-
temic anticoagulation. Systemic anticoagulation is the gold standard for inhibiting
clot formation on blood-contacting biomaterials but unfortunately it has been asso-
ciated with bleeding in many patients. Without systemic anticoagulation however,
clotting can lead to: blockage of blood flow paths and increased device resistance,
reduced mass transport in artificial lungs and kidneys, and thromboembolic events.
Paradoxically, clotting can also cause bleeding complications if platelets and clotting
proteins are consumed by artificial surfaces.
To date, clot formation and the accompanying life-threatening complications are
key problems clinicians still face. In attempts to reduce or eliminate the use of
systemic anticoagulation, two main approaches have been tried: 1) development of
surface coatings that inhibit protein adsorption (aka non-fouling surfaces) and 2)
heparin-bonded surfaces that inhibit the common branch of the coagulation cascade.
Clinical oxygenators that incorporate both of these anti-clotting approaches are avail-
able. Some examples are the X-coated Terumo Capiox; Carmeda (heparin-bonded)
1
and Trillium (polyethylene oxide) Medtronic Aﬃnity, heparin-bonded Medos Hilite,
and phosphorylcholine-coated Sorin PrimO2x. However, their clinical testing out-
comes have either been marginally beneficial for short term use (up to 4h) in car-
diopulmonary bypass settings or not diﬀerent from controls in long term use (weeks
to months) in respiratory support settings[1-3, 4].
Because of this unmet need, this research attempts to develop nitric oxide (NO)
releasing and generating surfaces and characterize their ability to inhibit clot forma-
tion and reduce the use of systemic anticoagulation. It examines a relatively new
approach to local inhibition of clotting on biomaterials through the use of NO gas.
NO is a free radical gas produced naturally by the endothelium and circulated in
biological systems to maintain hemostasis [5-8]. Endothelium NO flux levels have
been estimated in literature to be 1 - 5 (x10−10 mol min−1 cm−2).
Specifically, the work examines the synthesis of NO-generating and NO-releasing
polymers and determination of their NO flux rates. These NO-generating polymers
were then placed in oxygenators, and NO-releseasing materials were used to form
catheters. The thrombogenicity of these devices were then examined in vivo using
rabbits. Lastly, the NO flux rates were determined in vitro using a representative clin-
ical oxygenator and thoracic artificial lung using diﬀerent NO concentrations within
N2 as the sweep gas.
1.2 Coagulation on Artificial Surfaces
Under normal physiologic conditions, blood remains in contact only with the
normally antithrombogenic endothelium. The endothelium is lined with cells that
modulate hemostasis by expressing or secreting NO, thrombomodulin, heparan sul-
fate, tissue plasminogen activator (t-PA), urokinase plasminogen activator (u-PA) and
plasminogen activator inhibitors. Thrombomodulin and heparan sulfate inhibit blood
coagulation where as t-PA, u-PA, and plasminogen activator inhibitors modulate fib-
2
rinolysis [9]. Endothelial cells also have a low surface energy that keeps blood proteins
from changing conformation [10]. Artificial surfaces, however, lack such endothelial
properties and thus activate circulating platelets and the coagulation cascade leading
to blood coagulation.
Blood coagulation on biomaterials is initiated by the contact system. The liver
produces three main zymogens that play key roles in the contact system. These zy-
mogens, namely Factor XII (hageman factor), Factor XI, and high molecular weight
kininogen (HK) all exist in plasma. The initiation, activation, and feedback mecha-
nisms of these zymogens at the artificial surface is shown in Figure 1.1. In the ac-
Figure 1.1: The activation phase of the contact system A) starts with adsorption and
autoactivation of FXII. Activated FXII help activate prekallikrein (PK)
which exists as a complex with high molecular weight kininogen (HK). A
similar reaction occurs with FXI-HK complex resulting in the activation
of FXI. The system also uses a positive feedback mechanism B) where
FXII is rapidly activated by the activated form of PK, kallikrein (K). The
activation of HK is also potentiated by K. To balance the positive feedback
control, the contact system also uses a negative feedback mechanism C)
to halt the activity of XIIa and HK. It fragments XIIa into soluble/low
activity XIIf and inactive XIIi using K and fragments HK into surface-
bound inactive heavy chain HK (HKhc) and soluble light chain HK (HKlc)
using XIa. Modified from biomaterial science text 2nd Edition [ Colman
11]
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tivation phase, zymogen Factor XII first adsorbs to negatively charged surfaces and
activates to FXIIa by autoactivation. This process cleaves a single disulfide bridge of
FXII allowing its heavy chain to bind to the surface while revealing its active site. At
this point FXIIa becomes a co-factor for prekallikrein and FXI which exist in plasma
as non-covalent complexes with HK (PK-HK and XI-HK). The PK-HK complex binds
to FXIIa to activate prekallikrein into kallikrein. The FXI-HK complex also binds
to FXIIa to activate factor FXI into FXIa to complete the activation phase of the
contact system. Zymogens XII, XI, and PK at this point have been activated into
XIIa, XIa and K enzymes.
Once activated, the contact system uses a positive feedback mechanism poten-
tiated by kallikrein. Kallikrein acts on FXII and HK substrates to speed up their
conversion into FXIIa and HKa. For example HKa binds 10 fold faster than HK to
PK and FXI thereby accelerating the association PK and FXI. This feedback mech-
anism serves as the initial driver of all amplification reactions in blood coagulation
starting from the contact system down to a formed clot. The contact system also has
a negative feedback arm, in addition to the positive feedback mechanism, to mod-
ulate the contact system. During negative feedback control, Kallikrein cleaves oﬀ a
fragment of adsorbed FXIIa, (FXIIf), into plasma leaving behind inactivated FXIIi.
Although FXIIf is still active, its participation in blood coagulation is decreased as
it looses its aﬃnity for surfaces. It therefore exhibits low activity for prekallikrein to
kallikrein conversion. FXIa is also a player for the suppression of contact activation.
It cleaves oﬀ the light chain of adsorbed HK, HKlc, which contains the active site
of HK leaving behind the heavy chain portion (HKhc). This reaction terminates the
cofactor activity of HK and thus allows FXIa to desorb from the artficial surface.
The eﬀect of the negative feedback mechanism has however, not inhibited the contact
system adequately to prevent downstream activation of procoagulant factors in the
intrinsic and extrinsic pathways of the coagulation system that lead to clot formation
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in blood-contacting devices.
Post contact system blood coagulation has been traditionally viewed in two sep-
arate pathways; the intrinsic and extrinsic pathways. See Figure 1.2. Such views are
slowly fading as it’s now more accepted that the pathways interact in vivo.
Figure 1.2: The contact system involves the adsorption and activation of zymogens
FXII, FXI, and HK. FXIa from the contact system activates FIX of the
intrinsic pathway. A tenase complex consisting of FIXa and a phospho-
lipid surface (PL) in the presence of VIIIa and Ca2+ activates the FX. FX
activation marks the beginning of the extrinsic pathway and can occur
independently of TF (VIIa). However TF in the presence of a PL can
influence both pathways. With the production of Xa, a prothrombinase
complex is formed between FXa and FVa in the presence of a PL surface
(eg platelet’s membrane) to initiate the common pathway. Prothrombin is
converted into thrombin inside the platelet. After secretion from platelets,
thrombin potentiates the activation of XI, VIII and V to amplify blood
coagulation. Thrombin cleaves fibrinogen into fibrinopeptides A and B so
the peptides can polymerize into fibrin resulting in more fibrinogen-GP
IIb/IIIa interaction for a stable clot. Finally thrombin, activates FXIII
to cross link fibrin for a solid clot to form. Modified from biomaterial
science text 2nd Edition [11]
The contact system is viewed as part of the intrinsic pathway because it initiates
that branch of blood coagulation. The intrinsic pathway is associated with artificial
surfaces and consists of reactions involving only vascular elements that can occur
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independently of VIIa whereas the extrinsic branch consist of blood in addition to
vascular elements. The main diﬀerence between the branches lies in the way they
activate FIX. The intrinsic system uses FXIa in the presence of Ca2+ whereas the
extrinsic system requires tissue factor (TF) usually embedded in cell membrane lipid
bilayer in addition to calcium.
The intrinsic pathway is initiated by the activation of IX to IXa by Factor XIa
which is activated in the contact system. FIX can also be activated by TF in the
presence of a phospholipid (PL) surface and cofactor VIIa. For the next reaction to
occur, calcium, FIXa together with the tenase complex (phospholipid surface-cofactor
VIIIa) must work together to activate FX. This marks the end of the intrinsic pathway.
Activation of the extrinsic pathway is achieved again by TF in the presence of PL
and VIIa, the same coagulant elements association utilized in the intrinsic pathway.
As TF is present in endothelial tissue, activation of the intrinsic pathway is usually
associated with tissue damage. However, biomaterial-induced platelet activation and
inflammation can also activate the intrinsic branch, as TF is also present in platelets
and leukocytes. When TF associates with a PL and cofactor VIIa, FX is activated
into FXa marking the end of the extrinsic pathway and the beginning of the common
pathway of blood coagulation.
The common pathway is activated by the promthrombinase complex consisting
of FXa, cofactor Va on platelets’ membrane and a PL surface in the presence of cal-
cium. With FVa serving as the platelet membrane receptor for FXa, the activated
platelet produces and secrets prothrombin. The complexing of these four elements
to form prothrombinase increases prothrombin activity by 300,000 fold compared to
that achieved by FXa and prothrombin alone. Adsorbed and activated platelets on
the artificial surface, at this point, are connected by fibrinogen-glycoprotein IIb/IIIa
platelet membrane receptor bridges following cleavage of fibrinopeptide A and B from
fibrinogen. Platelet aggregation achieved by interconnecting-platelet- secreted fibrino-
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gen bridges is still a premature clot until thrombin crosslinks the platelet aggregate by
converting fibrinogen into longer fibrin strands that bind to activated platelets mul-
tiple times. Finally a solid clot is formed when thrombin activates FXIII to FXIIIa
to cross link the interconnecting fibrin.
Thrombin also potentiates the clotting process by activating FV, FVIII and FXI
(broken line in Figure 1.2). It is therefore viewed as the most potent clotting factor
in blood coagulation.
1.2.1 Platelet Activation
Circulating platelets are activated either after damage to healthy endothelium or
after blood exposure to an artificial surface. After damage to the endothelium for
whatever reason, the endothelium looses its integrity and has to remedy its environ-
ment in order to restore its vascular tone. To achieve normal haemostasis, ruptured
endothelial cells secret a ”sticky” protein called von Willebrand factor (vWF) to bind
to collagen in the exposed sub-endothelial layer so that circulating platelets can bind
to the opposite ends of vWF to form a seal at the damaged area. Glycoprotein Ib/IX
receptor on platelets membrane allows binding of vWF to activate platelets.
On artificial surfaces, the contact system activation leads to generation of FXa.
This, in turn, binds to FVa on platelet membrane to activate platelets. After the
initial phase where few platelets are activated, a second and massive platelet activa-
tion phase ensues. The release of clotting factors from platelets’ granules during the
first wave of activations acts to systemically activate a substantially large amounts of
circulating platelets to potentiate coagulation. Among the granule content released,
those of greatest physiological importance and their platelet membrane receptors are
listed in Table 1.1
During blood flow in blood-contacting devices, flow-induced shear stresses can
also lyse platelets to expel their procoagulant factors or just activate them. Platelets
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Table 1.1: Agonists secreted from platelets’ dense** and alpha* granules including
other potent agonists and their platelet membrane receptors
Agonist Receptor
**Adenosine diphosphate (ADP) P2Y12 receptor
**Serotonin 5-HT2A receptor (Serotonin receptor)
*Platelet activating factor (PAF) PAF receptor
*vonWillebrand factor (vWF) glycoprotein Ib/IX
*Platelet factor 4 (PF4) PF4 receptor
*Thromboxane A2 (TxA2) TxA2 receptor
*Thrombin Protease-activated receptor -1(human)
Collagen glycoprotein IV
Fibrinogen glycoprotein IIb/IIIa
[11]
can thus be activated by such mechanical force in addition to chemical induction
explained above.
1.2.2 Intracellular Mechanisms During Platelet Activation
Platelets are about 3-4 µm in diameter and have a trilaminar phospholipopro-
tein membrane. The membrane (Figure 1.3) consists of a plasmatic surface with
mucopolysaccharides and glycoproteins, a filamentous submembranous area serving
as a contractile system and a peripheral zone filled with adhesion and signal trans-
duction receptor sites [11]. As shown in Figure 1.3, these surface receptors activate
phospholipase C (PLC) after interacting with platelet agonists.
PLC activation is mediated by glycoproteins (G proteins). After PLC is activated,
it cleaves phosphotidyl inositol bisphosphate (PIP2) into Diacylglycerol (DAG) and
inositol triphosphate (IP3). IP3 then mobilizes Ca2+ from a dense tubular system
within the platelet cytosol to activate myosin light chain kinase (MLCK), which
phosphorylates the myosin light chain (MLC). This reaction is responsible for the
membrane contraction that changes the platelet’s shape from discoid to spherical.
Dense and alpha granules migrate to the center of platelet at this point. The Ca2+also
activates phospholipase A2 (PLA2) to initiate a series of reactions to produce throm-
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Figure 1.3: Intracellular mechanisms duing platelet activation: Modified from
Overview of Hemostasis [11]
boxane A2. On the other hand, DAG stimulates protein kinase C (PKC) which in
turn phosphorylates P47. The P47-PO4 then interacts with G proteins to expose
the platelet receptors active sites. Finally MLCK, P47-PO4, and thromboxane A2
together stimulate the secretion of platelet granules [11].
1.2.3 Clinical Consequences of Clotting on Biomaterials
The sequelae of blood activation in medical devices vary depending on the device
and its duration of use. During the use of extracorporeal membrane oxygenation
(ECMO), total artificial lung (TAL), arterio-venous CO2 removal (AVCO2R), ECMO,
TAL or AVCO2R, clots can impede gas transfer in and out of blood and increase
resistance to blood flow. In the case of a TAL, this can also increase the loading on
the right ventricle. Clots can also shed oﬀ the membranes and travel back into the
vasculature, lodge in major organs, cause organ dysfunction or failure, and potentially
lead to death.
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Because of such complications, some form of systemic anticoagulation is adminis-
tered to prevent thrombus formation in all of these applications. During ECMO, the
level of anticoagulation is monitored hourly by the whole blood activated clotting time
(ACT) method. Many extracorporeal life support centers maintain the ACT between
180-200 seconds compared to a normal reference value between 70-80 seconds. During
clinical TAL use and in low dose ACT AVCO2R regiment, ACTs are maintained be-
tween 180-200 seconds [12-13 ]. Such tight increments in average ACT from baseline
require much care, as small downturns in ACT can lead to significant clot formation.
High ACT, on the other hand, helps avoid clot formation but also predisposes the
patient to bleeding. For example, high ACT during cardio pulmonary bypass (CPB)
can lead to post-op bleeding complications, and high ACT during ECMO can lead to
bleeding complications, particularly in kids.
Clotting-related complications can also occur in total artificial lungs. Unlike
ECMO, where a pump is used to drive flow, here, TALs utilize the right ventricle
as the pump. Therefore, an increase in device resistance is especially problematic,
as it abnormally stresses the heart. Pumpless AVCO2R also lacks a pump, and can
suﬀer the low flow and reduced gas transfer problems seen in TALs.
The function of other blood-contacting devices like catheters and whole blood
sensors are also adversely aﬀected by protein adsorption and clot formation. Their
small surface areas (SA) decrease their platelet consumption compared to devices
with large SA to volume ratio. For such devices with large SA to volume ratios,
clotting can lead to rapid failure since it doesn’t take a large body of clot to occlude
the device. For example, the diameters of pediatric catheters are so small (21- 24 ga)
that it takes little masses of clot for occlusion to occur.
Clot formation also adds a finite layer of clot material onto biomaterials and can
lead to decreased gas diﬀusion across the biomaterial. In artificial lungs, for example,
the layer of clot creates an added physical barrier between the gas exchange fiber
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wall and flowing blood. During oxygenation, the sweep gas not only will travel the
normal fiber-wall length but also cross the clot thickness to reach flowing blood. The
increased gas diﬀusional distance is also true for AVCO2 where CO2 travels out from
blood into sweep gas.
Reduced gas transfer in gas exchange devices, increased resistant to blood flow,
and thromboembolic complications are all real clinical problems as a result of clotting
on biomaterials. These problems still need to be addressed with new approaches that
do not elicit other equally life-threatening complications.
1.3 Clinical Methods used to Control Coagulation
There are two main approaches being followed by current clinical practice to minize
the eﬀects of blood-biomaterial interactions. They include 1) systemic anticoagulation
and 2) surface modification of biomaterials.
1.3.1 Systemic Anticoagulation
The mechanism of action of these drugs on platelets and on the intrinsic pathway
of blood activation is summarized in Figure 1.4. The most commonly used systemic
anticoagulant is heparin, but other agents such as clopidogrel, aspirin, and warfarin
are also used. Heparins role in inhibiting clot formation is multi-faceted. It inhibits
factor Xa from activating prothrombin into thrombin and, when complexed with an-
tithrombin III, it directly inhibits thrombin from binding to platelets. It also partially
inhibits the activation of FXII and FXI. Warfarin inhibits Factors II and VII of the
extrinsic coagulation pathway, Factors IX, X, and prothrombin of the intrinsic path-
way. The points of action of both these anticoagulants are downstream of the onset
of blood coagulation and have no eﬀect on protein adsorption. Furthermore, these
anticoagulants may compromise hemostasis and cause hemorrhage as it acts systemi-
cally [14]. Aspirin and clopidogrel are also among the commonly used systemic drugs
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Figure 1.4: Fibrinogen-induced platelet activation on artificial surfaces
to inhibit platelet activation. Asprin irreversibly inhibits the synthesis of Thrombox-
ane A2 and prostaglandins inside platelets and Clopidogrel binds to platelets ADP
receptor, P2Y12, to block ADP from activating platelets. They inhibit the clotting
cascade at the biomaterial’s surface and inside platelets in an irreversibly manner
that can lead to bleeding complications [14].
The compilations from the use of both conventional and newer anticoagulation
drugs, their mechanisms of action, indications, and complications is summarized in
Tables 1.2 and 1.3 [15-19].
The response to these drugs diﬀer from patient to patient. In fact, many patients
are resistant to the eﬀects of a single oral anticoagulation drug, so sometimes a ther-
apy that embodies multiple drugs having diﬀerent mechanisms of action is often used.
The problem with this approach is that although the mechanisms of action for current
antiplatelet agents are known, their combined eﬀect may induce an anticoagulation
eﬀect whose magnitude may be too large to allow restoration to normal hemostasis.
Therefore administering these agents concomitantly further increases the potential of
bleeding and of other unforeseen complications [20]. Ultimately, these drugs increase
the risk of bleeding complications because of their prolonged half lives. Bleeding
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complications become even more devastating in patients with renal insuﬃciency who
cannot eﬃciently clear these long lasting drugs. The eﬀects of systemic anticoagula-
tion swing from bleeding in cases where it overwhelms hemostasis to device clotting
when inadequate concentrations are used. In devices with large surface area, both
eﬀects (bleeding and depletion of systemic clotting factors and platelets) can occur.
Bleeding complications from systemic heparinization are the most common and
life-threatening. For example, the Michigan ECMO experience with neonatal mor-
tality is one that can still be improved if bleeding complications due to systemic
anticoagulation are reduced. According to the most recent report on the impact of
ECMO on neonatal mortality [21], bleeding is the most frequent cause of death in
newborns managed with ECLS. In this population, intracranial hemorrhage occurred
in approximately 13% of neonates, 5% of pediatric patients, and 4% of cardiac pa-
tients. Clotting complications are also common, occurring in 26% of patients [22].
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Table 1.2: Conventional anticoagulation drugs; indications, mechanism of action and
complications
Conventional Anticoagulants
Drug Mechanism Indication Complications
Heparin Binds and activates
AT-III to inhibit
factor IIa and Xa
Prophylaxis in gen-
eral surgery, pre-
vention and treat-
ment of arterial and
venous thrombosis
Heparin-induced thrombo-
cytopenia (HIT): treatment
involves activation of platelets
with PF4 complexes
Warfarin
(Coumadin)
Inhibits synthesis
of vit-K dependent
factors II, VII, IX
and X
Venous thrombosis
and prevention
of venous throm-
boembolism in
patients with MI
Severe bleeding -Black stool or
bleeding from the rectum, -Skin
conditions such as hives, a rash
or itching,-Swelling of the face,
throat, mouth, legs, feet or
hands, -Bruising -Chest pain or
pressure, -Nausea or vomiting,
-Fever or flu-like symptoms, -
Joint or muscle aches, -Diarrhea,
-Diﬃculty moving, -Numbness
and tingling, -Painful erection
lasting four hours or longer
Aspirin Irreversibly inhibit
enzyme COX to
block thromboxane
A2
Prevention of
thrombosis in es-
tablished vascular
disease patients
-GI toxicity from gastric acid se-
cretion: Aspirin inhibits PGI2,
PGE2, PGD2 whose expression
are necessary for the inhibition
of gastric acid secretion from the
mucosa. -Renal toxicity: As-
pirin inhibits vasodilatory eﬀects
of prostaglandins and thus can
decrease renal blood flow leading
to renal insuﬃciency (microalbu-
minuria @ 325mg daily), Signif-
icant reduction in Na excretion
to 1500mg daily., -Hemorrhagic
Stroke: cerebral bleeding @
higher doses)
Clopidogrel ADP-platelet
aggregation irre-
versible
Patients with a
history of ischemic
stroke, MI
Inhibition eﬀect lasts over 4-
5days and bleeding times maxi-
mizes in 3-7days.
[15, 17 - 19]
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Table 1.3: New anticoagulation drugs; indications, mechanism of action and compli-
cations
New Anticoagulants
Drug Mechanism Indication Complications
Abciximab
(Reopro)
High aﬃnity for
GP IIb-IIIa non-
competitive, slowly
reversible, eﬀect
duration = 24-48h,
detected on circu-
lating platelets 2wk
after treatment
Prevention of car-
diac ischemia in
PCI, ACS (unsta-
ble angina)
Dosage led to 90% blocking of
GPIIb-IIIa receptors, marked in-
hibition of aggregation and pro-
longed bleeding time. Platelet
and RBC transfusion are re-
quired in CBP and stenting.
Near normal bleeding time seen
after 12h
Tirofiban
(Aggrastat)
Highly specific but
low aﬃnity for GP
IIb-IIIa, rapidly re-
versible, eﬀect du-
ration = 4-8h
Acute coronary
syndrome (ACS)
Excessive bleeding, pelvic pain,
slowing heart rate and dizziness
Eptifibatide
(integrilin)
Highly specific but
low aﬃnity for GP
IIb-IIIa, highly re-
versible, eﬀect du-
ration =2-4 h
Acute coronary
syndrome, Percu-
taneous coronary
intervention
Case study result:- Groin
hematoma: 179(1020), GI
bleading: 11(1020), Pulmonary:
1(1020), all in PCI patients.
Legend: observed(total)
[15, 17 - 19]
1.3.2 Clinical Coatings
In addition to systemic anticoagulation, biomaterial surface coatings are being
used clinically to control clotting. These coatings are largely of two types. The first
type attempts to bind heparin to the surface in order to inhibit coagulation specifically
at the surface of the biomaterial. The second focuses on limiting protein adsorption
to the biomaterial in order to inhibit activation of the contact system and the intrinsic
branch of the coagulation cascade.
Coatings that utilize heparin include of Duraflo II, Bioline, Sarns/3M and Carmeda
Bioactive Surface. As shown in Figure 1.5, the working principle of heparin for inac-
tivation of thrombin is a two-step process. Anti-thrombin III, secreted by the liver
into systemic circulation, must first bind to a specific pentasaccharide sequence on
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Figure 1.5: End-point bonded (ionic or covalent) heparin coating and mechanism of
inactivating thrombin (not drawn to scale).
immobilized heparin molecules to induce conformational changes in ATIII. In the
second step, systemic thrombin released from activated platelets binds to ATIII. The
ATIII-thrombin complex then turns oﬀ thrombin and dissociates it from the immo-
bilized heparin molecule. Whether immobilized in its unfractionated or fractionated
form, heparin’s activity is reduced for two reaons: 1) it is fixed and thus has limited
interaction with ATIII and with thrombin by extension and 2) its pentasaccharide
active site can be broken up due to processing.
Coatings that attempt to limit protein adsorption are Sorin and Dideco’s phos-
phorylcholine, trillium, and Terumo’s poly(2- methoxyethylacrylate) aka X-coating.
These coatings are designed to incorporate charge polarity to increase the hydrophilic-
ity and lower the surface energies of biomaterials by attracting water molecules[23-
24]. Water molecules cluster around polar functional groups of long chain grafted
molecules to create an aqueous layer at the blood/biomaterial interface. The func-
tional groups is believed to limit protein and platelet adsorption by presenting an
environment similar to aqueous state of plasma.
The Sorin phosphorylcholine (PC) coating consist of is a polar zwitterionic phos-
pholipid molecules. One end of the molecule is positively charged and the other
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phosphate end is negatively charged. Because of this zwitterionic nature, it’s able
to be absorbed on negatively charged surfaces with the phosphate end free. The in-
teraction of free end with water leads to water retention near the blood/biomaterial
interface [25]. Trillium coating consist of polyethylene oxide polymer chains that are
hydrophilic along its entire chain to create an insulating water layer [23-24]. X-
coating also consist of long chain polymers with a polar property and thus work in a
similar way as trillium and PC.
The eﬀectiveness of repelling plasma protein and platelets by these coatings de-
pends on how well they retain their water content. Although there isn’t data on that
under physiological flow conditions, these polymer chain coatings are prone to leach,
as is common in most coatings, and lose water retention during flow.
These coatings and their usage are summarized in Table 1.4. The two most com-
mon heparin coatings (Duraflo II and Carmeda Bioactive surface) have so far received
only general acceptance in routine clinical practice and their current use in the United
States is estimated at about 17% of all perfusions [26].
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Table 1.4: Clinical coatings available for blood-contacting surfaces and estimated
quantity used in US Clinics
Coating %Usage in all
perfusion
Manufacturer Current location
Duraflo II [heparin coating] ca 8.5 Edwards Life-Sciences Irvine, CA
Surface Modifying Addi-
tive [polydimethylsiloxane
polycaprolactone oligomer]
— COBE Cardiovascular Arvada, CO
Phosphorylcholine — Dideco Mirandola, Italy
Sorin Synthesis [Phosphoryl-
choline]
—
SORIN Group USA,
Inc
Arvada, CO
Bioline [heparin coating] — Jostra AG Hirrlingen, Germany
X Coating [poly(2-
methoxyethylacrylate)]
— Terumo Cardiovascular Ann Arbor, MI
Sarns 3M Heparin —
Sarns 3M Cardiovascu-
lar Systems
Ann Arbor, MI
Trillium Biopassive Surface
[polyethylene oxide]
—
Medtronic Cardiopul-
monary
Minneapolis, MN
Carmeda Bioactive Surfaces
[heparin coating]
ca 8.5 — —
[26- 33]
Surface coating with heparin is currently achieved mostly by ionic or covalent
attachment (see Figure 1.5). Carmeda, Bioline, and Sarns 3M covalently attach the
heparin by a general method described by Larm et al [28] whereas Duraflo II surfaces
are coated with heparin by ionic attachment. There are however, slight variations in
the method of covalent heparinization used by Bioline and Sarns 3M. Biolines coating
method employs a linker molecule (e.g. natural material such as polypeptides) to
bind the heparin to the polymer. The linker molecule provides sites of both ionic
and covalent interactions with heparin and as a result a more stable bonding of the
heparin molecule is achieved [29]. The heparinization technique of 3M company is
similar to that used by Carmeda Bioactive coatings. It involves a covalent binding
of an oxidized heparin to a layer of coated biomaterial. Duraflo II heparin coating
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is an ionically bound benzalkonium- chloride complex which enables relatively firm
connections with the surface compared to Carmeda. However, a general disadvantage
of this method is the rapid release of heparin upon exposure to blood or plasma [30].
In the covalent attachment method, the reaction in heparin can occur only at one
end allowing the heparin molecule to be tethered only at one end with the remainder
containing the active site free to interact with flowing blood. Theoretically, this end-
point attachment method may be eﬀective than ionic attachment, as the free end of
the heparin would increase its interaction with blood.
In a study conducted by Niimi et al [34] where heparin-coated polypropylene
surfaces and uncoated controls were primed with whole blood and incubated for 3hrs,
no change in platelet activation between groups was observed. Also there was signif-
icant platelet adhesion within each group (p <0.05). A decade later, Fluger et al
[35] also studied the eﬀect of ionically bonded heparin coating on fibrinogen (Fg) ad-
sorption, platelet counts and activated partial thromboplastin tim(aPTT) in 60 CPB
patients. Half of the patients were assigned to a tip-to-tip heparin coating circuit
and the other half were put on uncoated circuits. The levels of Fg in the coated and
non-coated groups dropped significantly (p<0.0001) from 2.90 to 2.44 mg/dL and
from 2.73 to 2.40 mg/dL respectively after 2hrs postoperative. There were also no
diﬀerences in aPTT and platelet counts between the two groups.
In works involving PMEA coatings, Tanaka et al [36], Kocakulak et al [37],
and Demirkilic et al [38] conducted an in vitro study where various forms of poly
(meth) acrylates were tested for platelet adsorption and an in vivo study using PMEA
coated CPB circuits in 96 patients. Platelet deposition in the Tanaka study was low-
est (4 x 104 cells/µm2) on PMEA out of six other forms of poly (meth) acrylates
tested. Kocakulak et al found significant loss of platelets in coated and uncoated
groups by the end of surgery (p<0.01). Also, significantly more platelets were lost in
the uncoated group (116 000 cell/mm3) than in the coated group (36 000 cell/mm3),
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p < 0.01. Plasma Fg was also lost more in the uncoated group (1.3 g/L) than in the
coated group (0.25 g/L) although both groups significantly (p<0.01) lost Fg at the
end of CPB. Demirklic et al’s work where they combined PMEA tip-to-tip coating
of CPB circuits and optimized extracorporeal circulation for reduced turbulent flow
showed especially fascinating results. Baseline Fg and platelet count levels were not
diﬀerent from levels at the end of CPB in 41 patients. The only weakness in that
study is that PMEA-coated circuits were not controlled for with uncoated circuits and
therefore it’s diﬃcult to evaluate the anticoagulatory property of the PMEA coating.
Was the result solely PMEA-coating eﬀect one?, a combination of flow optimization
and coating?, or just flow optimization?
Studies similar to those described have also been conducted with Trillium, phos-
phorylcholine, surface modifying additives and modified heparin coatings. Stammer
et al [2], Ereth et al [1], Noora et al [39], and Van den Goor et al [40]
have studied Trillium biopassive coated oxygenator versus uncoated ones in a CPB
setting. In Ereth’s study only the oxygenator was coated and their results suggest
that Trillium coating showed no clinical benefit. Levels of BTG, Fg and platelet count
were no diﬀerent between coated and uncoated oxygenators (p=0.05). Stammers et al
raises a good question about this study; ”Was the treatment of the oxygenator alone,
and not the entire circuit, suﬃcient to show eﬃcacy?”. A definite interpretation of
Ereth’s study is therefore diﬃcult to make. In other work conducted by Noora et al,
coated CBP circuits containing a Trillium-coated Medtronic membrane oxygenator
was compared to uncoated circuits in 256 patients. Noora et al concluded that the
coating showed no inter-group diﬀerences in platelet counts. This observation was
also confirmed in Van den Goor’s work where no diﬀerence in platelet count (p=0.17)
was observed between two groups (N=10 patients/ group). One group were treated
on Trillium-coated circuits and another on uncoated CPB circuits. There was also no
diﬀerence (p=0.47) in contact system FXIIa between groups.
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The water retention property of polar zwitterionic phosphorylcholine head groups
has established the molecule as a potential material for coating biomaterials to inhibit
blood coagulation [25]. Some research groups have classified it as a biocompatible
material based on in vitro and in vivo studies in animals [33, 43]. Outcomes from
clinical studies however don’t quite put PC coating in such light. In a study con-
ducted by De Somer et al [41], Farneti et al [42] and Stefano et al [43],
PC coating was evaluated for its ability to inhibit blood coagulation during CPB in
many patients. In De Somer’s work, randomly selected 25 patients were treated with
PC-coated CPB circuits whereas the other 25 received uncoated circuits. No diﬀer-
ences in generated thrombin and platelet counts were observed between the groups
(p < 0.01). Platelet factor 4 and BTG levels in the uncoated group (22192 ± 17931,
8040 ± 3986 IU/mL) were however significantly higher (p=0.01, p=0.005) than in
the coated group (9338 ± 17303, 3790 ± 4104 IU/mL). A diﬀerent outcome in BTG
levels was reported by Ferneti and Stefano. In their studies a tip-to-tip PC-coated
CPB circuits and uncoated controls were evaluated in a total of 50 adult patients.
No significant diﬀerences in BTG and sP-selectin was observed between tip-to-tip
PC-coated and uncoated groups (p>0.05). Furthermore when CPB was performed
under diﬀerent blood management conditions (blood suction, shed blood separation
and without shed blood separation) to reduce blood trauma associated with CPB,
platelet counts still decreased with no diﬀerences observed between PC-coated and
uncoated groups (p>0.05). In all three conditions, however, platelet counts did not
drop significantly (p= 0.2, 0.13, 0.46) in both control and PC-coated groups.
Other polymers with similar hydrophilic properties exhibited by PC has also
been developed and tested clinically. These polymers termed surface modifying
additives (SMAs) are incorporated into the blood-contacting biomaterial during pro-
cessing. SMAs such as polycaprolactone and PDMS are amphiphilic so they poses
both hydrophilic and hydrophobic groups. When incorporated into biomaterials dur-
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ing processing in aqueous conditions, the surface of the biomaterial gains hydrophilic-
ity as the hydrophobic tails of SMAs orient towards and attach to the biomaterial.
Based on this chemistry, SMA-coated surfaces have been tested clinically for its anti-
coagulatory properties. In one such study Defraigne et al [44] compared COBE
SMARxT extracorporeal Circuits (COBE Laboratories, Gloucester, England) to un-
coated controls using procoagulant markers’ levels as metrics in 100 CPB patients.
The coated surface preserved more platelets (165±9 X 103/mm3) than in uncoated
circuits (137±8 X 103/mm3). However, platelet counts decreased and BTG levels
increased significantly in both groups (p< 0.01). In addition the biocompatibility of
SMA-coated surfaces was not adequate to eliminate or reduce the normal systemic
heparinization regiment (ACT > 400) common to all the CPB studies described
herein.
A relatively new form of surface coating consisting of heparin modified with long
chain dialkyl group has also been tested in goat for its antithrombogenecity in a tip-
to-tip coated ECMO system in Japan by Nishinake et al [45]. Hydrophobicity of
dialkyl groups is proposed to reduce heparin leaching from coated polymethylpentene
hollow fiber membrane oxygenator and other ECMO circuitry during blood circu-
lation. This group provided long-term respiratory support for 151 days with small
doses of heparin infusion while maintaining the concentration of pro-coagulant mark-
ers close to physiological levels. Baseline, week 1 and 21 ACTs were 118, 125 and
133 s respectively. ACTs were stable between during the test period. Platelet counts
remained almost steady for 4 weeks and gradually decreased thereafter. Baseline,
week 1 and 21 values were 51.9, 48.5 and 15 X 104/mm3 respectively. ATIII levels
remained in physiological range with baseline, week 1 and 21 values of 127, 124 and
138%. Unfortunately no clinical trials of this coating exist.
Of the several studies comparing diﬀerent surface coatings using identical or al-
most identical research protocols to allow for direct and accurate evaluation, the
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most relevant work starting from about a decade ago is discussed here. Palanzo et
al [46] and Hoel et al [47] compared Duraflo II (ionic bonded heparin) to Trillium
(polyethylene oxide) coatings in a total of 90 CPB patients using procoagulant mark-
ers’ levels as metrics for blood coagulation. In both studies there were no diﬀerences
in the demographic data of patients who were attached to Duraflo II or to Trillium
coated circuits. The Palanzo study reported a 6.2±10.2% drop in platelets (corrected
for hemodilution) after 20 mins in patients who were assigned Trillium coating and
3.6±15.8% in the Duraflo II coating group. Platelet count drop were not significantly
diﬀerent within and between groups. Platelet counts within groups may have been
diﬀerent if blood samples were drawn at the end of the CPB and analyzed for counts.
In addition to platelet counts, Hoel et al also monitored beta thromboglobulin (BTG)
concentration. Platelet counts in their study decreased significantly (p <0.0005) in
Duraflo II and Trillium groups with no significant inter-group diﬀerences. There
was a 40% and 60% drop in platelet counts in the Trillium and Duraflo II groups
respectively. Correspondingly, BTG also increased significantly (p=0.02) in both
groups. The authors concluded that using either the Carmeda-coated oxygenator or
the Trillium-coated oxygenator aﬀords similar benefits in regards to preserving circu-
lating platelet counts during bypass.
In 2000, Larson et al.[48] compared Duraflo II and Sarns 3M heparin-coated arte-
rial filters. The heparin-coated surfaces were evaluated for thrombus formation in a
4hr veno-venous extracorporeal circulation models using adult pigs. Clots formed on
coated arterial filters were analyzed with macro-densitometry, light microscopy, and
scanning electron microscopy. The conclusions drawn from this study were that the
3M circuit had significantly less gross thrombus (p < 0.001), 66% and 84% less micro-
scopic thrombi and five-fold less SEM-measured aggregates (p = 0.03) compared to the
Duraflo II and uncoated groups. This may be interpreted to mean that the Sarns 3M
surface is less thrombogenic. However, if closely inspected, another interpretation of
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the data emerges; there was a 25% decrease in platelet count in the 3M and uncoated
groups and a 13% decrease in the Duraflo II group over the study period. Perhaps,
adhered platelets on the Sarns 3M coating remained in the state of microaggregates.
The surface areas of circuits used in respiratory support methods are quite larger
than an arterial filter’s surface area. Hence a better study approach would have been
testing tip-to-tip coated circuits. This work, perhaps, does not provide enough sci-
entific evidence to conclusively compare the two heparin-coated surfaces. Thiara
et al [49] have also studied another heparin-coating product called Bioline. Bioline
surfaces are composed of covalently-bonded heparin coating similar to Sarns 3M coat-
ing. Bioline and PC-coated CPB circuits were evaluated for their anti-coagulability in
30 patients undergoing either valve replacement or coronary artery bypass grafting.
Platelet count was used as the metric for measuring anti-coagulability of coatings.
Platelet counts decrease significantly in PC (15% drop) and Bioline (17%) groups (p
= 0.01). No diﬀerence in platelet counts was observed between groups (p = 0.66).
In a slightly diﬀerent study, the additive anti-coagulation eﬀect of heparin cova-
lently bonded on arterial line filters and oxygenators in PC-coated CPB circuits was
evaluated in 15 patients. The other 15 patients were attached to uncoated oxygena-
tors in PC-coated circuits. Jacobs et al 2011 [50]observed a significant increase in
platelet factor 4 (PF4) in both groups after the CBP procedure (p < 0.001). PF4
level in both groups increase from about 25 IU/ml to about 150 IU/ml. No additional
benefit in combining both coatings was observed.
The Thiara group further evaluated a tip-to-tip PC-coated PVC circuit connected
to PC-coated Avant oxygenator and a tip-to-tip X-coated PVC circuit connected to
X-coated Terumo oxygenator for anti-coagulability in 30 CPB patients [51]. Platelet
count, thrombin-antithrombin III (TATIII), and lactate dehydrogenase (LDH) levels
were used as metrics for analyzing anti-coagulation. TATIII levels significantly in-
creased from 6.1 and 7.4 µg/L at baseline to 12.5 and 10 µg/L at the end of surgery
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in PC and X-coated groups respectively (p < 0.05). Platelet count also significantly
decreased from 220 X 109/L and 198 X 109/L at baseline to 186 X 109/L and 172 X
109/L in PC and X-coated groups respectively (p < 0.05). Expectedly, LDH levels
significantly increased in both groups (p < 0.05).
Gunaydin et al [52], Marcoux et al [53] and Hussaini et al [54] have
conducted anti-coagulability studies on multiple clinical coatings including carmeda,
trillium, x-coating, bioline and phosphorylcholine in CPB procedures. On average,
platelet count drop of 39.2 ± 6.2% was recorded across all 5 coating groups. Other
procoagulant markers such fibrinogen consumption, BTG and PF4 all change at sig-
nificant (p < 0.05) or close to significant levels in the direction indicating inadequate
inhibition of coagulation.
The recurring theme in blood anti-coagulability testing of commercial coatings in
CPB is one that range from marginal clinical benefits to generally non-significant dif-
ferences when compared to non-functionalized biomaterials. It is however, important
to note that CPB is a highly invasive procedure associated with a substantial amount
of trauma on blood elements as a result of surgery and chest tube drainage of blood.
Blood elements can thus be activated by CPB procedures completely independent of
blood-biomaterial interaction. Perhaps, this is the reason why these coatings have
performed better in ECMO and in vitro settings. For example, Nojiri et al group were
able to support adult sheep on an ECMO circuit coated tip-to-tip with heparin for up
168 h with minimal heparinization (ACT = 150 sec). Gas transfer remained stable
and platelet count remained within the physiologic range throughout the experiment
[55]. Matsuwaka et al 1990 also evaluated covalently bonded heparin ECMO circuits
with an uncoated pedriatric centrifugal pump in dogs for 12 h without systemic hep-
arinization. No significant diﬀerences in gas exchange and no apparent macroscopic
thrombus formation was observed. [56].Similar conclusions have also been reached by
Palmer et al 1995 [57]. Taken together this body of knowledge on commercial coat-
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ings show better anticoagulation in less invasive test settings like simulated ECMO,
and no significant anti-coagulatory benefits in CPB [58-60].
1.4 Experimental Surface Modifications for Improved Hemo-
compatibility
There are other surface modification techniques being experimentally tested in in
vitro settings. These methods are highly experimental in nature and may take years
of research to advance it to clinical testing. They include attachment of charged (neg-
atively, positively or zwitterionic) molecules, polymer brushes, albumin, derivatives of
hydrophilic groups (ethylene glycol, ethylene oxide, methyl ether methacrylate)[61],
and air, oxygen or nitrogen plasma treatment of biomaterials’ surfaces. A few of
these methods have been reported on extensively in the literature and are discussed
herein. The immobilization of hydrophilic groups (eg tetraglyme) on biomaterials
keep a hydration layer on their surfaces to prevent protein adsorption and their sub-
sequent denaturation that initiates activation. Hydrophilic groups are mostly either
attached as self-assembled monolayers (SAMs) with diﬀering terminating groups or as
brushes of diﬀerent chain lengths. The ability to control the terminating groups ( e.g.
hydrophobic (methyl), hydrophilic (hydroxyl and carboxyl), and a binary mixture of
both) lends this technique a great versatility in chemically modifying the surfaces of
biomaterials.
An in vitro study by the Ratner group, [62] showed that by varying ratios of
hydroxyl and methyl terminations of SAMs diﬀerent eﬀects on human fibrinogen ad-
sorption and platelet adhesion and activation can occur. Platelet adhesion was about
50 and 98 % less (p < 0.05) on SAMs with 65% and 100% hydroxyl groups, respec-
tively when compared to a gold surface and SAMs terminated with less than 65%
hydroxyl after exposure to plasma. This could be explained by the higher albumin
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aﬃnity for the SAMs with 65% hydroxyl and the lower total protein adsorption as-
sociated with SAMs with 100% hydroxyl. After exposing these surfaces to a protein
solution with a similar ratio of fibrinogen and albumin to that existing in blood (0.1
mg/ml fibrinogen +1mg/ml serum albumin), SAMs with 0%, 36% and 65% hydroxyl
showed c.a. 70%, reduction in fibrinogen adsorption. On the same SAMs configura-
tions but with lower serum albumin (0.1mg/ml serum albumin), a 30% reduction was
observed indicating, perhaps, a higher albumin aﬃnity of SAMs with 65% hydroxyl.
This raises the question of whether engineering surfaces to create higher aﬃnities
to specific plasma proteins can reduce the adsorption of procoagulant ones. Most
of these new surfaces are yet to be to applied to commonly used blood-contacting
biomaterials and tested in in vivo settings for thrombogenicity evaluation.
Anchorage of polymer brushes to glass, silica, aluminum and gold is another sur-
face modification method being tested. Polymer brushes are end-tethered (anchored,
grafted) polymer chains stretched away from the substrate due to excluded-volume
eﬀect. See Figure 1.6.
Figure 1.6: High density grafting of polymer brushes
The concept of excluded volume, introduced by a Physical Chemist Werner Kuhn,
states that the excluded volume is the volume inaccessible to other molecules in the
system as a result of the presence of the first molecule. This eﬀect help brushes
extend out from their base into the interacting medium creating a larger physical
barrier between substrate and particulates of medium. In the case where hydrophilic
brushes are used, blood elements may perhaps interact less with substrate due to such
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large hydration layer sequestered by brushes. Single type polymer brush or a mixture
of polymer brush grafting is a reality today and have been tested for biocompatibility
[63] and microbicidal and biofilm resistance properties in some cases [64]. Because
these brushes can be terminated with antimicrobial peptides (AMPs) like cathelicidin,
not only can the surface be imparted with hydrophilicity arising from a polar brush
but it can also actively kill microbes and thus prevent biofilm formation.
1.5 Long Term Use of Oxygenators
Artificial lungs are built to function similar to the natural lung: transport oxygen
into the bloodstream and remove carbon dioxide from it. These devices work in a
similar fashion to the natural lung, with the gas flowing on one side and blood on
the other side of a gas permeable membrane. Gas exchange occurs by diﬀusion of the
gases across the membrane. Artificial lungs are used in several diﬀerent long-term
applications: ECMO, AVCO2R, and TAL. The design, surface area, and clot for-
mation in these devices varies based on application. Typical ECMO, AVCO2R, and
TAL artificial lungs have gas exchange surface areas of 2.5, 1.3, and 1.7 m2 respec-
tively, and the typical gas exchange membranes are composed of polypropylene (PP),
polymethylpentene (PMP), or polydimethylsiloxane (PDMS). In ECMO circuits, up
to 0.5 m2 additional surface area is possible when one considers the pump, heat ex-
changer, reservoir, and tubing in the system. The AVCO2R and TAL circuits only
consist of the device and its cannulae or vascular grafts, and thus contain less than 0.1
m2 additional surface area. Extracorporeal membrane oxygenation (ECMO) involves
the use of a modified heart-lung machine to support life for patients with severe, acute
respiratory or cardiac illness [65].
Total artificial lungs (TALs) have been used to support animals [65] for up to
30 days. In humans, the duration of respiratory support continues to push to the
limit. The maximum time on ECMO for newborns is usually around 21 days, and
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the record for longest survivor on ECMO in the US is at 62 days [66]. This record
was broken in January 30, 2008, when a patient at National Taiwan Univeristy hos-
pital, Taiwan survived a drowning accident after 117 days of ECMO application [67].
These durations of support are isolated cases. Problems that limit long-term ECMO
support includes bleeding associated with heparinization, thrombus formation in cir-
cuit, oxygenator failure, plasma leakage in some oxygenators, and decreased immune
function. ECMO is generally a bedside technology so patients are less ambulatory
which may lead to muscle atrophy and reduced immune function.
Gas transfer membrane materials of oxygenators are a key design choice for all of
these devices. They must be highly gas permeable to allow gas diﬀusion for blood
oxygenation and/or carbon dioxide removal, be highly non-thrombogenic to reduce
blood activation and subsequent thrombus formation on their surfaces, and ideally
prevent plasma leakage through the membrane during long term support. Commonly
used materials in clinical oxygenators include polypropylene (PP), polymethylpentene
(PMP) and silicone rubber. Polypropylene fibers are microporous, PMP fibers are
porous on the gas side but contain a solid skin on the blood side, and silicone rubber
fibers are solid throughout.
Microporous membranes create smaller gas diﬀusional distances and are thus more
eﬃcient at oxygenation and CO2 removal. As published by Gaylor et al. [68], the
resistance to O2 and CO2 transfer in microporous membranes is small and their
hydrophobic property is maintained during conditions pertaining to CPB. In long
term extracorporeal life support however, membrane resistance may increase due to
progressive wetting of the microporous structure which lead to plasma leakage, a
condition marked by yellowish to orange coloration in the oxygenator. To resolve this
problem, plasma tight PMP microporous membranes were introduced. This hybride
membrane is microporous with a thin solid wall to separate blood and gas sides. Until
a couple of years ago, there were no reported incidences of plasma leakage with the
29
hybrid membranes. In 2009, Luis et al [69] described the occurrence of plasma leakage
in a plasma-tight polymethylpentene type oxygenator after 24h of ECLS. Obviously,
there is no denying the fact that the three primary complications of ECLS described
above can and need to be improved; some more than others.
The outstanding challenge in extracorporeal life support today is limiting compli-
cations due to biomaterial-induced blood activation and subsequent thrombus forma-
tion. Many of the current solutions to these problems are decades-old, and alternate
ideas for controlling blood coagulation should be pursued.
1.6 Nitric Oxide: Mechanisms and Physiology
Nitric oxide gas holds significant promise as an antiplatelet agent at a biomaterial
surface. It aﬀords the luxury of local inhibition of clotting without the use of systemic
anticoagulation. Nitric oxide is synthesized by the brain, macrophages [70], liver
[71], and most importantly by endothelial cells. NO production by endothelial cells
is most relevant for regulating blood tone. Other regulatory functions within cells and
tissues include vasodilation, neurotransmission and as a bactericidal agent secreted by
macrophages. NO is formed in the body directly from guanidino nitrogen of the amino
acid L-arginine through a two-step reaction catalyzed by nitric oxide synthase (NOS).
30
Figure 1.7: Biosynthesis of NO. L-arginine is converted to NO in two successive steps
of which a two-electron oxidation of L-arginine to N-w-hydroxy-L-argninie
is the first, then converted to NO and citrulline, utilizing one and half
NADPH and O2. Both steps require Ca2+ and calmodulin as activators
and are accelerated by tetrahydrobiopterin [72]
It’s a process that consumes five electrons, and results also in the formation of
L-citrulline. The complete reaction is shown in Figure 1.5. NG-hydroxy-L-arginine
(NOHLA) is formed in the intermediate step and the overall reaction consumes 1.5
moles of nicotinamide adenine dinucleotide phosphate (NADPH) [73] and 2 moles of
molecular oxygen [74]. The unpaired electron on the biosynthesized NO gas makes
it highly reactive giving the molecule extremely short half life (2-5 seconds) in blood
[75]. Such a short half life limits the molecule to act local to the site of production.
Since it is both water/lipid soluble, it diﬀuses freely within tissues from its site of
formation to its site of action. It has been reported to bind to the heme moiety
of guanylate cyclase, an important molecule also present in platelets, and cause a
greater than 400-fold activation of the enzyme[76]. These properties are essential for
applications that require fast-acting and potent eﬀect of NO on platelets.
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1.7 Inhibition of Platelet Activation by Nitric Oxide
In the vasculature, endothelial cells produce NO as described in 1.6 for regulating
several physiological processes. After production, the gas diﬀuses into flowing blood
and it’s either oxidized or taken up by blood elements like the platelet. Because NO
is lipohilic, it freely crosses the lipid bilayer of platelets to indirectly activate several
intracellular reactions leading to inhibition of platelet activation. See Figure 1.8.
Figure 1.8: Intracellular nitric oxide-cyclic Guanosine Monophospate dependent
pathway model that keeps platelets from activation
These reactions termed the NO/cyclic cGMP pathway are initiated by the activa-
tion of soluble guanylyl cyclase after NO binds to its heme centers [75 - 76]. Soluble
guanylyl cyclase then hydrolyzes guanosine triphosphate (GTP) into 3’, 5’- cGMP. To
inhibit platelet activation, the activated cGMP prevents several of the intracellular
platelet activation reactions from occurring [77]. It can phosphorylate G protein-
coupled surface receptors of the platelet. Their phosphorylation results in a change
in their conformation which disorients their binding sites to decrease binding aﬃnities
of agonists. Commonly known G protein-coupled receptors on the platelet include
thrombin, thromboxane A2, and adenosine diphosphate receptors. Other ways that
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cGMP helps inhibit platelet activation include blocking the activation of PLC, block-
ing the intracellular release of calcium, and blocking the activation of PLA2. The
blocking mechanisms are important because PLC is required to initiate G-couple
protein mediated platelet activation, calcium release is needed for actin-myosin inter-
action so that platelets can contract and release their granules and PLA2 is needed to
synthesize the secreted clotting agent thromboxane A2. Collectively, these eﬀects on
adhered platelets or those proximal to the source of NO production reduce secondary
activation of circulating platelets.
As shown in Figure 1.8 NO produced by the endothelium can also end up binding
to other NO scavengers like ceruloplasmin and hemoglobin in RBCs [78 - 79].
Figure 1.9: Fate of NO in blood. After production, NO can be taken up by platelets,
RBCs, or oxidized into nitrites by ceruloplasmin, a multicopper oxidase
concomitantly with cupric (Cu2+) to cuprous (Cu+) reduction. Perhaps,
with other NO scavengers in plasma, only a fraction of the NO gener-
ated diﬀuses into platelets to activate the NO/cGMP pathway to inhibit
platelet activation.
Therefore, the availability of NO to platelets not only depend on the quantity of NO
produced by a surface but also on competitive binding to NO by other scavengers.
Physiological reactions of NO with Hb during respiratory cycle in RBCs has shown
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interesting dynamics contrary to the general knowledge of which NO irreversibly bind
to Hb. In this model, NO binds to Hb, dissociates and gets transnitrosated to cysteine
in a cycle as a mechanism for controlling the bioactivity of NO in blood vessels. These
interactions occur during the journey of relaxed Hb (Hb fully saturated with oxygen)
from arterioles back to arteries after crossing the lung. Transnitrosation occurs at the
beta subunits of Hb so potentially in one cycle at least 50% of bound NO could be
transferred to cysteines as 2 out of the 4 subunits of Hb are of the beta type [80-83].
The gas could also be oxidized into nitrites by ceruloplasmin, a plasma oxidase
produced by the liver. Ceruloplasmin is a multicopper oxidase and converts NO into
nitrite concomitantly with cupric (Cu2+) to cuprous (Cu+) reduction.
Ultimately, the diﬀerent fates of NO reduces its immediate availability to platelets.
The gas can however be recovered from blood thiol groups that received NO from Hb
and from nitrates by catalytic decomposition and reduction reaction. It’s important
to also note that the gas will again be presented with the same fates all over again.
1.8 NO-releasing and NO-generating Polymers
As knowledge of NO inhibition of platelet activation expanded, it was only a
matter of time until the multifaceted molecule found its way into blood-contacting
materials. The first work on diazeniumdiolate NO donors incorporation in polymers
was published in 1996 [84]. In the past decade however, published work in this
research area has mainly focused on material synthesis optimization methods for
controlled and sustained NO concentration at the blood/polymer interface. Polymers
functionalized in attempts to impart those properties have been done by 1) entrapping
of NO donors in their matrices, 2) doping their surfaces with catalysts to either
catalyze endogenous NO donors or both endogenous and exogenous NO donors, and
3) tethering peptides that have high aﬃnity for NO (e.g cysteine) onto their surfaces
to direct transnitrosation towards the polymer.
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Entrapment methods studied so far include direct dispersion of diazeniumdiolates
(N2O2−) in polymers, covalent attachment of the N2O2− either to side chain groups
or to the backbone of the polymer, and dispersion of amines in the polymer followed
by pressurising the polymer with NO in a high pressure atmosphere [84-96]. These
diﬀerent entrapment mechanisms, including covalent bonding of N2O2− to nano/micro
spheres which are then dispersed in a polymer, are done to increase the NO storage
capacity of polymers, and control the release of the gas.
In works involving entrapment of N2O2−, Smith et al showed an NO flux of about
0.0001 x 10−10 mol/min/mg for 160 hrs from poly(caprolactone) doped with N2O2−,
Zhang et al [95]showed 4 x 10−10 mol/min/cm2 for 4 hours from silicone rubber
doped with DACA-6, Robbins et al [96]showed 3.6 x 10−10 mol/min/cm2 for 24 h
from sensors coated with sol-gel siloxanes previously doped with amines and pres-
surized under 5 atm of NO(g) for 24 h, Stasko et al [94] showed 5.6 µ mol/mg for
16 h from generation 5 dendrimers that were functionalized with amines and then
pressurized with NO (5 atm), Riccio et al [90] showed 1.31 µ mol/mg (1 x 10−10
mol/min/cm2) for 2 weeks from xerogels doped with NO using similar conditions,
and later showed 4.39 µ mol/mg total release from nanometer silica particles modi-
fied with N2O2−. These fluxes demonstrate the ability to functionalize polymers to
release NO at levels comparable to that produced by the endothelium (0.4 - 5 x 10−10
mol/min/cm2). However, these relatively short release duration do not to satisfy clin-
ical requirements for long-term usage of NO releasing materials. They must be able
to sustain endothelial levels of NO release for months, however the limited amount of
N2O2− that blood-contacting devices can hold makes such long-term release a diﬃcult
challenge.
Other research groups have therefore investigated catalytic methods to extend the
useful lifespan of these materials. This approach does not rely on storing NO inside the
polymer but rather on catalysts to react with blood-borne or exogenous NO donors to
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generate NO. The production of NO at the biomaterial’s surface continuously occur
as long as the catalyst and NO donor interaction remains intact. Oh et al [97] showed
≥ 1 x 10−10 mol/min/cm2 NO flux from PVC doped with lipophilic Cu(II) complex
using 0.5 mM nitrite as the NO donor and 1 mM ascorbate as the Cu(II) reducing
agent, Cha et al [98]showed a 200 ppb NO generation from Polyethylenimine and 3, 3’
dipropionicdiselenide mixed with selenium in solution phase using 0.5 mM EDTA as
the NO donor and 250 mM GSH as the reducing agent, Hwang et al [99] showed 2 x
10−10 mol/min/cm2 from polymethacrylate doped with lipophilic Cu(II), and Major
et al [100]showed 12 x 10−10 mol/min/cm2 from PVC doped with 10 wt% 80nm
Cu(II) particles used for coatings on extracorporeal circulation circuits using 0.5 mM
nitrosogluthation and 1 mM gluthathion. The fact that these catalytic methods also
yield endothelial NO flux levels provides a potential solution for long term generation
of NO.
Tethering of cysteine on biomaterials for production of NO at their surfaces via
transnitrosation has been reported by Duan et al [101]. To measure transnitrosa-
tion, cysteine tethered polyethylene terephthalate films were exposed to bovine serum
albumin-NO (BSA-NO) NO donor in 20 mM PBS for 3 hrs and the transnitrosation
was measured by the drop in BSA-NO concentration BSA-NO concentration moni-
tored. After 3 h, BSA-NO concentration decreased by 67% from 4.50 to1.5 µM indi-
cating a transfer of NO from BSA to cysteine. Such surfaces have not produced high
NO fluxes, as seen in a study published in 2010 by Kushwaha et al [102] where a flux
of 0.019 x 10−10 mol/min/cm2 was recorded. An new functionalization paradigm that
is now receiving increased attention is the combination of NO and other endothelial-
like properties like heparan sulfate and thrombomodulin. This research area, however,
has not evolved enough to evaluate its potential. One such study that demonstrates
this paradigm was conducted by the Zhou et al [103] group. They attempted this
approach to some degree but much about their function is still a puzzle. Important
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conclusions that can gathered from those in vitro studies are that, the activity of
heparan sulfate and thrombomodulin diminishes when immobilized and longer chain
linkages between the base polymer and tethered agent may improve activity. The
eﬀect of adding other functional groups on NO production at the biomaterials surface
is yet to be fully evaluated.
The performance of the above NO functionalized surfaces in terms of flux levels
and in vitro and in vivo are summarized in Table 1.5. These results collectively show
that NO-functionalized polymers with higher levels of endothelial NO flux inhibited
platelets activation more that polymers with low NO flux levels. For instance, as
shown in Figure 1.10, surfaces that released ≥ 1x10−10 mol/min/cm2 of NO showed
a significant inhibition of clot formation compared to non-NO releasing controls after
16 h implantation in porcine arteries [104].
Table 1.5: Nitric oxide (NO) flux levels and inhibition of platelet activation by NO
releasing/generating polymers
Test duration Average NO flux Eﬀect on Platelets REF
(h, h*) (x10−10 mol/min/cm2) (control/NO polymer)
160,1*in vivo 0.0001 2.5/0.25 billion a,1 [84]
4,4*in vivo 4 35±5/14±3%a,2 [95]
24,24*in vitro 3.6 120± 47/28±18% coverage b,3 [96]
16, — 5.6 µ mol/mg — [94]
336,1*in vitro 1.31µ mol/mg 205±64/149±8 a,4 [90]
0.5, — 4.39µ mol/mg — [93]
NA, – ≥ 1 — [97]
NA, — 200ppb (liquid sample) — [98]
NA, — 2 — [99]
NA, 4*in vivo 12 42.5±4.3/15±2 % a,2 [100]
30, 48*in vitro 0.019 73000±22000/470±220 a,5 [102]
h,h* : Test durations for NO flux, and material biocompatibility
3 : Platelet coverage measured by percent opaqueness in a 167x167 µm2 image area relative to glass control
1 : Platelets deposited, 2 : Platelets lost, 4: Adhered platelets, 4: Adhered platelets/ cm2
NA : No NO production limit on NO generating sample, a: p<0.05, b: p<0.001
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Figure 1.10: NO flux profile (A) of an electrochemical oxygen sensing catheter coated
with DACA-6/N2O2−/silicone rubber. NO release was measured via
chemiluminescence in PBS buﬀer (pH 7.4) at 378C. Representative dig-
ital (B) and SEM (C) images of DACA6/N2O2SR-coated sensors and
control sensors after implantation in porcine arteries for 16 h[104].
1.9 Sweep Gas Nitric Oxide for Artificial Lungs
Previous methods of functionalizing biomaterials with NO via entrapping finite
amounts NO donors and by means of catalytic decomposition of endogenous NO
donors involve a chemical modification of the biomaterial. These methods have not
yet been applied to artificial lungs as fiber fabrication is a highly specialized process.
The application of such methods to artificial lungs requires a merger of industrial
type facilities and engineering/chemistry expertise currently unique to the academic
setting. With blood clotting in artificial lungs still a problem, an easier alternative
for supplying NO to the biomaterial surface is delivering NO gas directly to the sweep
gas. In this approach, NO gas is flowed simultaneously with oxygen into oxygenators
in order to reduce clot formation inside the device.
A wide range of sweep gas NO concentrations have been supplemented in sweep
gas to reduce platelet adhesion, activation, and coagulation within oxygenators in
vitro and in vivo with mixed results. Platelet inhibition by low sweep gas NO con-
centrations have shown mostly positive results in vitro and negative ones in vivo.
Results from in vivo studies conducted using higher sweep gas NO concentrations
(>500ppm) have, however, trended towards higher significance in terms of inhibiting
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blood anticoagulation.
Mellgren et al [105] evaluated the non-thrombogenecity of extracorporeal circu-
lation circuits during heparinized blood flow through a (Dideco D-901 hollow fiber
oxygenator) for 24 h using three diﬀerent sweep gas concentrations (15, 40, and 75
ppm) that were infused at 0.6 L/min. Plasma nitrate, cyclic guanosine monophos-
phate, and platelet count were significantly higher and Beta thromboglobulin was
significantly lower in the NO circuits than in the control circuits (p<0.01). No dif-
ference was observed in platelets serotonin content and membrane glycoprotein Ib
density between circuits. There were no dose-response eﬀects in all measured vari-
ables for the NO concentrations tested. Similar positive results using low sweep gas
NO concentration (20ppm) were also reported by Keh et al 1999 [106]. In their study,
the NO gas was supplied into M18 Jostra oxygenators in a simulated ECMO circuit
primed with 1IU/ml heparinized blood. Platelet count, betathromboglobulin, and
methemoglobin concentrations were monitored in the circulating blood (0.6 L/min)
for 4h. Platelet count and methemoglobin concentrations were significantly higher
(p<0.01) in NO group than in controls. Betathromboglobulin was also significantly
lower in the NO group (p<0.05).
In an in vivo study conducted by Lowson et al. such positive results seen in
the above in vitro low-dose NO settings were not observed even at a slightly higher
sweep gas NO concentration of 100ppm. Inhibition of platelet activation in membrane
oxygenators attached to 47 CPB patients was no significantly diﬀerent from controls.
Furthermore, NO had no eﬀect on betathromboglobulin concentration and bleeding.
Methemoglobin concentration also remained below 4% in both NO and control groups
during the 3 h procedure [107]. In a diﬀerent study where 500ppm sweep gas NO
concentration was used in swine undergoing CPB, platelet adherence and aggregation
decreased compared to their controls (p<0.05) [108]. NO also had no eﬀect on blood
flow, mean arterial pressure, and hematocrit concentration. A summary of these
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studies and other relevant work indicating sweep gas NO concentration and their
eﬀect on blood clotting is presented in Table 1.6.
Table 1.6: Eﬀect of sweepgas NO concentrations on blood coagulation
Sweepgas NO
concentration
Test duration Inhibition of blood coagula-
tion
REF
(ppm) (h, setting) (control/NO sweep)
15, 40, 75 24, in vitro 162/175 x 1011 Pct,∗∗ [105]
2000/2600 (IU/ ml) bTG
20 4, in vitro 50/72% Pct,∗∗ [106]
3000/2500 (IU/ ml) bTG,∗
1.25±.07→1.38±.06/1.43±.05→3.5±.23
(IU/ ml) metHb,∗∗
80 (in O2) 6, in vivo 5.78±3.8/0.54±0.41% Sc,∗ [107]
62/58 (%) Pct,∗
40 3, in vivo 60/60% Pct [108]
100/100% Pfunc
<1%/<1% metHb
100 3, in vivo <1%/<4% metHb [109]
153±32/178±57 x103/µL %
Pct,∗
500, 1000 1.5, in vivo 2/0.2 x 1011 Pct,∗ [110]
<1%/4% at 500ppm and 8% at
1000ppm metHb
Pct,∗∗ : Platelet count, p<0.01, bTG : Beta-thromboglobulin, Sc,∗ : Surface coverage, p<0.05
Pfunc : Platelet function, metHb : methemoglobin
The mixed results may be due to wide variations from study to study in NO con-
centrations, oxygenator types, blood flow rates, and in vitro and in vivo models. The
in vivo models were all CPB models, a procedure accompanied with a substantial
amount of biomaterial-independent platelet activation. So evaluating sweep gas NO
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concentration using only a CPB model, perhaps, doesn’t eﬀectively access the antico-
agulatory eﬀect of the NO gas. Each of the factors above is, however, likely to aﬀect
NO flux rates from the gas exchange membrane. These flux rates have never been
measured or modeled, making interpretation of the results diﬃcult. A visit back to
the drawing board to investigate what sweep gas NO concentration would produce
endothelial levels of NO flux in various commercially available oxygenators is a good
metric for evaluating NO’s anti-coagulatory performance.
1.10 Summary of the Study
In brief, this study presents a motivation behind the need to explore alternative
methods for controlling thrombus formation on blood-contacting biomaterials. Espe-
cially, coagulation on artificial surfaces, clinical consequences of clotting for various
artificial devices, current methods used to control clotting, the current state of long-
term use of respiratory support devices (oxygenators), the potential of nitric oxide
releasing and generating surfaces and in sweep gas for controlling thrombus formation
on blood-contacting surfaces, and future biomaterials are addressed in Chapter I. For
research work involving biocompatibility testing of the gas exchange membranes of
oxygenators, NO generation via catalytic decomposition of endogenous NO donors
and sweep gas NO were selected a the methods for surface functionalization with
NO. These methods allow for long-term release of NO and thus may work for long-
term respiratory support. NO donor entrapment method was utilized in the catheter
research work to lay a foundation for optimizing catheters for a long term NO release
and non-thrombogenecity testing.
Chapter II explores the synthesis and characterization of NO generating silicone
for use as a blood-contacting biomaterials. In this alternate approach, copper at the
biomaterial surface is utilized to generate NO from donors within the blood flow.
Surfaces with various copper concentrations were characterized for NO flux, clotting
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times, and platelet adhesion. The applicability and limitations of the NO-generating
surface are also presented.
With knowledge gained from Cu-mediated NO generation from silicone mem-
branes, Chapter III explores the application of Cu catalyst to hollow silicone fibers
for NO generation. In brief the development and NO flux characterization of hollow
silicone fibers are presented here. Small diameter fibers were extruded to incorporate
various Cu particle sizes and diﬀerent particle distribution using similar manufac-
turing conditions used in industry. Their NO generation as a function of particle
size and distribution was evaluated so that the best combination of particle size and
distribution may be used for developing the first NO-generating artificial lung.
In the next chapter, Chapter IV, our in-house material synthesis conditions were
carried over for the fabrication of gas-exchange hollow silicone fibers that can also
generate NO at Medarray Inc. facilities. NO flux from these fibers was characterized
before fabricating the first NO-generating oxygenator prototypes. The prototypes
were evaluated for their thrombogenicity against non-NO-generating controls in an
extracorporeal circulation thrombogenecity model using a tip-to-tip coated circuits
and adult rabbits. In brief this chapter provides the first thrombogenicity outcomes
of a Cu-mediated NO-generating oxygenators.
Chapter V explores the application of NO-donor dispersion approach for NO re-
lease, as opposed to NO generation, to small diameter silicone catheters. The chem-
istry of NO-releasing material synthesis, NO-releasing catheter fabrication and their
non-thrombogenicity were characterized in vivo using a thrombogenic rabbit model.
Specifically, the thrombogenicity of controls (non NO-releasing) are compared to NO-
releasing catheters in a 4h study. This chapter provides a fabrication method for de-
veloping NO-releasing catheters, a thrombogenicity testing regiment and points the
way forward for long-term NO-releasing catheter fabrication and testing.
NO releasing and generating methods of functionalizing blood-contacting surfaces
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show a promising future. However what if we can bypass the chemistry involved by
just purfusing artificial lungs with commercial sweep gas NO? With a wide range of
sweep gas NO concentration tested with mixed results, Chapter VI, explores the use of
nitric oxide sweep for reducing thrombus formation in oxygenators by characterizing
the nitric oxide flux in two diﬀerent commercial oxygenators in vitro. Estimation of
NO flux across clinical oxygenator membranes are made for several nitric oxide sweep
gas concentrations. This study provides a better estimate of what sweep gas NO
concentration will yield endothelial NO flux levels for starters. This results may find
importance in nitric oxide sweep gas studies where flux control is pertinent.
Finally Chapter VII discusses contributions, limitations, and future works.
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CHAPTER II
SYNTHESIS AND CHARACTERIZATION OF
NITRIC OXIDE-GENERATING SILICONE FOR
USE AS A BLOOD-CONTACTING
BIOMATERIAL
2.1 Abstract
Coagulation upon blood-contacting biomaterials remains a problem for clinical
applications lasting anywhere from hours to years. The following study examined
the ability of copper(II)-doped silicone surfaces to generate nitric oxide (NO) and
inhibit coagulation at the biomaterial surface. Silicone was doped with 3-micron
elemental copper (Cu) particles yielding 3, 5, 8, and 10 weight percent (wt%) Cu
in 70 µm thick Cu/Silicone polymeric matrix composites (Cu/Si Polymetric matrice
composite (PMC)s). At 3, 5, 8 and 10 wt% Cu doping, the surface expression of
Cu was 12.1 ± 2.8%, 19.7 ± 5.4%, 29.0 ± 3.8%, and 33.8 ± 6.5% respectively. Cu
expressed on the PMCs surfaces was observed to primarily coalesced into dendrites.
After oxidizing elemental Cu to Cu(II) by spontaneous corrosion the surface NO
flux, JNO (mol cm−2 min−1), as measured by gas-phase chemiluminescence, increased
with surface Cu expression according to the relationship JNO =(1.63 %SACu - 0.81)
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x10−11, R2 = 0.98 where %SACu is the percentage of the surface occupied by Cu.
The maximum flux measured at 10 wt% Cu was 5.35 ± 0.74 x10−10 mol cm−2 min−1.
Clotting time of sheep blood exposed to these surfaces increased with Cu content
from 80 ± 13 seconds with pure silicone to 339 ± 44 seconds with 10 wt% Cu(II)
added. SEMs of NO-generating coatings showed clots occurred away from exposed
Cu-dendrites. Cu/Si PMCs inhibit coagulation in a dose-dependent fashion related
to the extent of copper exposure on the coated surface.
Keywords: Nitric oxide, Cu(II), silicone, platelets, coagulation
2.2 Introduction
Over 200 million blood-contacting biomaterials are presently used in clinical ap-
plications such as catheters, vascular grafts, heart valves, extracorporeal membrane
oxygenation (ECMO), cardiopulmonary bypass circuits, artificial kidneys, ventricular
assist devices, glucose sensors, and stents [1]. In all these applications, it is impor-
tant to reduce surface-induced blood activation in order to increase the useful life
of the device and reduce thromboembolic complications. Thrombosis is especially
problematic in long-term clinical applications such as artificial lungs (arteriovenous
CO2 removal, ECMO, thoracic artificial lungs) where the need for eﬃcient gas trans-
fer requires a larger surface area [2]. Currently, the administration of conventional
systemic anticoagulants such as heparin, low-molecular-weight heparin, warfarin, as-
pirin, and clopidogrel is standard clinical practice to inhibit blood coagulation. Usage
of newer Glycoprotein (GP)IIb/IIIa blockers like reopro, aggrastat and integrilin to
achieve the same goal are also on the rise [3]. Unfortunately, these anticoagulants act
systemically and have long half-lives. Thus, they limit coagulation at the artificial
surface, at surgical sites, and within native blood vessels. The result is longer device
lifespan but also increased risk of bleeding complications [3 - 5].
A relatively new approach to reduce clot formation on biomaterials is through
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surface release or generation of NO [6,7]. NO is a free radical gas produced by the
endothelium to maintain hemostasis [8 -11]. The gas reduces platelet activation by
inhibiting agonist binding to their surface receptors. It freely diﬀuses into platelets
to initiate the NO/cyclic guanosine monophosphate (cGMP) [10,11] pathway that in
turn phosphorylates G protein-coupled surface receptors, changing their conforma-
tion to decrease binding aﬃnities of agonists. Commonly known G protein-coupled
receptors on the platelet include thrombin, thromboxane A2, and adenosine diphos-
phate receptors. The gas also reduces secondary activation of circulating platelets by
inhibiting the release of platelets intracellular granules. This is achieved by block-
ing the release of their calcium stores needed for actin-myosin interaction that is
required for platelets to change their shape and release their granules. Unlike other
platelet inhibitors, NO has a very short half-life (milliseconds), as it is quickly taken
up by RBCs, platelets, and other NO scavengers. Thus, the anticoagulant eﬀect oc-
curs near the surface that releases or generates NO and has no eﬀect on coagulation
downstream.
NO generation from polymeric materials impregnated with Cu and other transition
metal particles has been described [6,7]. In brief, these metallic particles catalyze
the release of NO from NO-donors in blood. In the case of Cu, the metal exists
mostly as Cu(II) on the surface of the polymer after oxidation. Reducing agents
convert Cu(II) to Cu(I), which then interacts with NO-donors(Figure 2.1) to produce
thiolate ions, Cu(II), and NO gas. The thiolate ions then combine to form disulfides
by reducing Cu(II) back to Cu(I). The entire reaction repeats to continuously generate
NO. As shown also in Figure 2.1, numerous reactions aﬀect the concentration of NO
in blood. In addition to binding and inhibiting platelets, NO can form nitrites by
oxidative species, including ceruloplasmin,[12 ,13] and bind to hemoglobin and form
methemoglobin. Plasma deoxyhemoglobin can also reduce NO2− back to NO. Plasma
deoxyhemoglobin is normally associated with blood trauma caused by extracorporeal
62
Figure 2.1: Cu-mediated NO generation model (6). The in vitro NO generation from
these surfaces, ( 2.1a), can be measured accurately however the amount of
NO generated in vivo from these surface still remains in question. Cerulo-
plasmin, a multicopper oxidase synthesized and secreted by the liver into
plasma catalyzes the oxidation of NO into NO2 concomitantly with cupric
(Cu2+ ) to cuprous (Cu+ ) reduction (13, 14). Perhaps, with other NO
scavengers in plasma, only a fraction of the NO generated diﬀuses into
platelets to activate the NO/cGMP pathway to inhibit platelet activation,
( 2.1b).
circulation during CPB or ECMO.
These modified polymers could be used to coat blood contacting surfaces or the
blood-contacting device could be constructed wholly out of NO-generating materials.
For example, the artificial lung’s gas exchange membrane could be made wholly from
silicone that is doped with Cu. To this end, the following study characterizes the
relationship between the surface exposure of Cu surface NO flux, and the resultant
anticoagulant eﬀect from a silicone-Cu polymeric matrix composite (Cu/Si PMC).
The aim is to provide a guide to their future use in any device with significant blood-
biomaterial interactions.
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2.3 Materials and Methods
2.3.1 In vitro Test System
An in vitro test system was created by coating standard Hemochron tubes (P214
flip-top, ITC, Edison, NJ) with PMC at various weight percents of Cu. The tubes
were emptied of their kaolin activator, rinsed with deionized water, and dried before
coating. Three micron particles of elemental Cu (Sigma Aldrich Chemical Co. St.
Louis, MO) were blended into part A of a two-part R21-2615 silicone resin (Nusil
Silicone Technology,CA). An equal volume of silicone resin Part B was added followed
by one mL of acetone per two mL of blend. The mixture was then stirred and
sonicated (Branson 5510 Sonicator Bath, Norwich NY) for 60 minutes to create a
uniform suspension. Cu microparticles were then added to create 0, 3, 5, 8, and
10 weight percent (wt%) Cu/Si PMCs. Cu/Si PMCs. The hemochron tubes were
loaded with 0.3 mL of the mixture and rolled over a flat surface to eliminate uncoated
patches. The tubes were then loaded horizontally into a rotisserie (Figure 2.2) and
cured by rotating the tubes in the x-y plane at 1.5 rev min−1 for 24 hours at ambient
temperature.
The resulting coatings had thicknesses of 70 m approximately. All cured coats
were later oxidized at 37◦ C for 24 hours by bathing them in PBS at pH 7.4 using the
Innova 4000 incubator shaker. Bathing in PBS oxidizes Cu to Cu(II) by spontaneous
corrosion of metallic copper [6], thus creating a Cu/Si PMC. The hemochron tubes
were then rinsed for approximately 2 minutes with deionized water and dried for
testing.
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Figure 2.2: 24hr curing of coated hemochron tubes in ambient temperature at 1.5 rev
min−1. The slow curing speed allows resin to uniformly coat the lumen.
All tubes ware capped with their flip tops during curing.
2.3.2 PMC Surface Analysis
The presence of Cu on the Cu/Si PMC was verified with energy dispersive x-ray
spectroscopyenergy dispersive x-ray spectroscopy (EDS) (EDAX Inc. Mahwah NJ).
The Cu/Si PMC layer was coated on to tubes as described above, but peeled and
sectioned into two cm2 pieces prior to oxidation and further testing. Twelve surface
locations per wt% were then analyzed with EDS. The following settings were used:
input count rate = 1000cps, energy resolution = 135eV, peak/background = 100, and
the scanned surface area = 4 mm2. SEMs of surfaces analyzed with EDS were then
imported into Image J (NIH, Bethesda, MD) for quantifying the percentage of Cu
exposed on the surface. The images were converted into a two-dimensional black and
white binary map and then processed using the particle analysis package to quantify
the percentage of total surface area occupied by Cu.
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2.3.3 Measurement of NO flux and Clotting Times
NO generation from 0, 3, 5, 8, and 10 wt% PMC-coated tubes (N = 6 each) was
measured by gas-phase chemiluminescence. Specifically, 2.75 ± 0.5 cm2 coated pieces
of the hemochron tube wall were introduced into a 1 µM S-nitrosoglutathione (S
nitrosoglutathione (GSNO)) to activate a chemiluminescence reaction in a standard
setup as shown in Figure 2.3. The NO generation profiles are decaying, left-skewed
Gaussian curves (See Figure 2.7). A peak NO flux is reached initially; thereafter the
GSNO concentration decreases and NO flux decreases. NO generation was measured
for at least 30 minutes from each sample, and the peak flux was recorded for presen-
tation. Clotting times of sheep blood were measured for the 0, 3, 5, 8, and 10 wt%
Cu-doped PMC-coated tubes (N = 6 each) using the coated hemochron tubes. Non-
heparinized sheep blood (0.4ml) was dispensed into the tubes immediately after being
drawn. Unlike typical activated clotting time assays, the tubes did not contain any
procoagulant activator. Thus, the artificial surface was the only activator present. All
other methods, including detection of a formed clot, followed standard Hemochron ac-
tivated clotting time protocols. Thus, clotting time was measured as the time elapsed
between loading the Hemochron tube with blood and when the Hemochron detected
solid clot. All in vitro clotting time experiments were performed in atmospheric level
of PO2, or approximately PO2 = 150 mmHg
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Figure 2.3: Chemiluminescence reaction and reaction setup.
2.3.4 Clot Distribution on NO-generating Cu(II)/Si PMCs
To examine the mechanism of anticoagulation, Hemochron tubes were coated with
0 or 10 wt% Cu-doped silicone and filled with approximately 5 ml of blood. The tubes
were placed on an Eberbach model EL687 shaker (Eberbach Labtools, Ann Arbor,
MI) at 50 cycles/min within a 37◦ C incubator for 30, 60, 90, 240, 360, and 480
seconds. After incubation, the surfaces were gently rinsed with saline solution until
the eﬄuent was clear and fixed with 2% gluteraldehyde (Sigma Aldrich Chemical Co.
ST. Louis, MO). The samples were imaged with a Philips XL30 FEG SEM to examine
protein adsorption and platelet adhesion to the surface.
2.3.5 Statistical Analysis
One-way analysis of variance (ANOVA) with Tukey’s post hoc tests was performed
to compare the dependent variables NO flux, clotting times and surface area of Cu
using the weight percent of copper as the independent variable. A p-value < 0.05 is
regarded as significant. All data is expressed as mean ± standard deviation.
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2.4 Results
2.4.1 PMC’s Surface Microstructure and Composition
In Figure 2.4, the surfaces of control and Cu(II)/Si coatings show diﬀerent surface
morphologies. As expected particle aggregates are not present on control surfaces,
whereas dendrites of Cu microparticles are present on the non-control surfaces. The
presence of Cu dendrites, as verified by EDS microanalysis, is shown in Figure 2.5.
SEMs of the Cu/Si PMC showing Cu dendrites were first analyzed with energy dis-
persive spectroscopy. The result showed a mapping of Cu in Figures 4.4B and 4.4C
similar to the Cu dendrite pattern of the SEM in Figure 4.4A. The energy spectra in
Figure 4D also shows the corresponding Cu peaks.
The percentage of the surface area of membranes occupied by Cu was quantified
with image J (NIH, Bethesda MD) to be 12.1 ± 2.8%, 19.7 ± 5.4%, 29.0 ± 3.8% and
33.8 ± 6.5% at 3, 5, 8 and 10 wt% Cu doping respectively (see Figure 2.6). These
results are significantly diﬀerent from 0 wt% group and from each other (p < 0.05).
The only exception is that the percentage of Cu/Si surface area occupied by Cu on
the 10 wt% Cu surface was not significantly diﬀerence from that of the 8 wt% Cu
group.
Figure 2.4: Surface of silicone coated control (A) and surface of Cu(II)/Si PMC coat-
ing showing Cu dendrites necessary for nitric oxide generation (B).
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Figure 2.5: Energy dispersive X-ray microanalysis results confirming the presence of
Cu on Cu/SI PMC coated surfaces: SEM of Cu/Si PMC showing Cu
dendrites (A) were analyzed with energy dispersive spectroscopy. The
result showed a mapping of Cu in the L (B), and K (C) shells similar to
the Cu dendrite pattern of the SEM. The energy spectra in D) also shows
the corresponding Cu peaks.
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Figure 2.6: The percentage of silicone surface-Cu as function of wt% Cu increased
from 12.90% at 3wt% Cu to 33.82% at 10wt%Cu. The percentage of
surface Cu in each wt% Cu coating group was significantly diﬀerent from
control and from the each other (p < 0.05). The only exception was that
the 10 wt% Cu group was not significantly diﬀerent from the 8 wt% Cu
(α = 0.05).
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Figure 2.7: Representative NO generation profiles for 0 (Control), 3, 5, 8, and 10 wt%
Cu PMC coated surface.
2.4.2 Relationships among wt% Cu, Surface Expression of Cu and NO
Flux and Clotting Times of PMCs
The peak NO flux increased with surface expression of Cu from 2.13 x 10−10 ±
0.38x 10−10 mol cm−12 min−1 at 3 w% to 5.35 x10−10 ± 0.73x 10−10 mol cm−2 min−1
at 10 wt% (Figure 2.8). The average peak flux of each group is significantly diﬀerent
from control and from each other (p < 0.05). The one exception is that flux from
the 10wt% Cu group was not significantly diﬀerent from that of the 8wt% Cu group
(p = 0.4). These fluxes were all greater than published human endothelial NO flux
in the range of (0.5 - 4) x10−10 mol cm−2 min−1 [12]. A linear fit of the relationship
between NO flux and wt% Cu yielded JNO = (-0.15wt%2 + 6.3wt% + 4.5) x 10−11,
R2 = 0.99.
Accordingly, clotting times increased with wt% Cu from 80 ± 13 seconds at 0
wt% Cu to 339 ± 44.5 seconds at 10 wt% Cu (Figure 2.8). The average clotting time
of each group is significantly diﬀerent from control and from each other (p < 0.05).
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Figure 2.8: Average clotting time and NO flux from PMC coated surfaces for 0 (Con-
trol), 3, 5, 8, and 10 wt% Cu polymeric matrix composites. The average
clotting time and average peak NO flux of each group is significantly dif-
ferent from control and from each other (p < 0.05). However the clotting
time and peak flux of the 10wt% Cu group was not significantly diﬀerent
from that of the 8wt% Cu group (p = 0.29 and p = 0.4 respectively).
However the clotting time of the 33.8 ± 6.5% Cu surface expression group was not
significantly diﬀerent from that of the 28.9 ± 3.7% Cu surface expression group (p
= 0.29). A linear fit of the relationship between clotting time in seconds (CT) and
surface expression yielded CT = 8.08(%SACU) + 55.71, R2 = 0.94.
2.4.3 Clots on Coated Surfaces
Scanning electron micrographs of clots on control and NO-releasing surfaces are
shown in Figure 2.9. Following exposure to blood for diﬀerent durations, an adsorbed
protein layer was present at all times, indicating that NO had no significant eﬀect
on total protein adsorption. However, Cu-doped surfaces had a smaller number of
adhered platelets. In particular, it can be seen that areas around exposed Cu dendrites
are free from platelets. Thus, the eﬀect of NO on coagulation appears to be primarily
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Figure 2.9: SEMs of Cu/Si polymeric matrix composite surfaces (PMCs), demon-
strating platelet adherence to control (0 wt% Cu) and 10 wt% Cu mate-
rials after 30 and 480 seconds. It appears that the adsorbed protein layer
was present at all times, indicating that NO had no eﬀect on protein ad-
sorption. In addition the Cu-doped surfaces had less adhered platelets
and the area around exposed Cu dendrites are free from platelets. Thus,
the eﬀect of NO on coagulation appears to be primarily keeping platelets
from adhering and perhaps keeping platelets that adhere from activating.
keeping platelets from adhering to the adsorbed protein layer and perhaps keeping
platelets that adhere from activating.
2.5 Discussion
Overall, these results indicate that Cu catalyzes NO formation eﬀectively in these
Cu/Si composites, and the NO formation leads to significant inhibition of clotting.
Clotting times were 1.33 and 4.24 times longer at 3 and 10 wt%, respectively, than
without Cu. Furthermore, the NO flux and resultant increase in clotting time is
dependent primarily on the amount of copper exposed on the surface of silicone. At
higher Cu weight percents, however, there are diminishing returns to adding more
copper. The surface concentration of copper does not increase significantly between
8 and 10 wt% (Figure 2.6), as increasing amounts of Cu get trapped inside the bulk
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material. Thus, there is little improvement in NO flux and clotting time at higher
Cu concentrations. Thus, at greater than 8%, a significant amount of copper is
buried within the bulk material and not assisting in NO generation. If greater NO
generation were desired, surface processing would be necessary. A base layer of pure
silicone could be laid down first, followed by a second, far thinner layer with a high Cu
concentration. The thin layer would keep Cu from being subsumed within the bulk
material. In the case of artificial lung membranes, this technique would reduce overall
copper content and might better maintain the gas permeability of the membrane.
These results also indicate that each wt% surface was capable of NO fluxes on the
same order as endothelial cells [14]. However, in vivo NO flux will depend on the con-
centration of a variety of NO-donors in present in blood and the reaction rate between
each donor and Cu(I). In blood, the total concentration of GSNO and other low molec-
ular weight NO donors such as S-Nitrosocysteine (CysNO), S-nitrosohomocysteine
(HCysNO), and S-nitrosocysteinylglycine (CysGlyNO) in healthy subjects ranges
across several orders of magnitude, from nanomolar to micromolar concentrations
[15,16]. Thus, predicting NO fluxes in blood are diﬃcult. In this study, 1µ M of
GSNO was used as the substrate for in vitro studies. The concentration of GSNO in
blood is about one-third of that used here, 320 ± 60 nM, but this is augmented by
the presence of the low molecular weight NO donors. In addition, the rate of reac-
tion between Cu(I) and these donors is faster than between Cu(I) and GSNO [17].
Thus, NO generation and the rate of clot formation may be diﬀerent in vivo and vary
across test subjects. Generation of NO will also vary with time. If not supplemented,
concentrations of NO donors will decrease as these molecules are cleaved to generate
NO. In situations in which small surface area devices such as stents and arterial and
venous lines are used, consumption would be minimal. In large surface area devices
such as artificial lungs, consumption would be rapid, as there will be more catalytic
sites for NO generation and widely studied synthetic RSNOs supplements such as
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S-Nitrosoglutathione and S-Nitroso-N-acetylpenicillamine (SNAP) would likely have
to be infused into the device inlet to maximize the local NO generation. SNAP will
be better suited for infusion, as it has been shown to be more stable than other
S-nitrosothiols that lead to inconsistency due to their highly unstable nature[18, 19].
Ultimately, choosing an appropriate level of copper for a biomaterial depends
greatly on the application. First, the minimum amount of Cu should be used to avoid
any potential risk of high blood Cu concentrations. The amount of leached copper
was not calculated here because of the short blood exposure times. In this study, at 10
wt%, 60 mg of copper was used per coating over a surface area of 33 cm2. If a similar
coating were applied to a stent (surface area = 6 cm2) and adult sized oxygenators
(surface area up to 25,000 cm2), the total amount of Cu that could potentially leach
would be 10 mg and 45,000 mg respectively. Thus, even if all of the Cu leached from
stents, the amount would be negligible compared to the recommended daily intake.
The amount that could leach from adult size oxygenators is higher than the tolerable
daily intake, but this amount would leach slowly over the devices lifespan. Moreover,
it is likely that only surface exposed copper would leach in significant amounts.
The rate Cu leaching into plasma has been studied in a 4 h, rabbit model of
extracorporeal life support [20]. There, a 10 wt% Cu circuit with a surface area of
0.02 m2 was used in 2-3 kg rabbits. The long term Cu leaching of these surfaces was
also addressed by measuring the Cu content over seven days in a similar, saline filled
extracorporeal circuit. There was a two-fold increase in plasma Cu to 5.9 ± 0.2 µg/dl
after 4h. After 7 days, Cu levels in saline was 23.4 ± 8 µg/dl. This indicates a very
slow rate of copper corrosion to copper ions within the coatings containing copper
nanoparticles.
Additionally, the level of Cu that should be used will depend on the application
and its duration. Large bore cannulae with relatively small surface area to volume
ratios and high blood flow velocities will require lesser amounts of NO release, whereas
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artificial lung surfaces, with high surface area to volume ratios and low blood flow
velocities will require far more NO release. Moreover, the longer the application, the
greater anticoagulation required. This study indicates that weight percents between
5% and 8% would be the most likely therapeutic range if the copper were in the bulk
polymer. Despite these positive results, this study is limited by the short periods of
blood biomaterial contact and the relatively static setting. Future long-term in vivo
studies are needed to determine the eﬀectiveness of the Cu/Si PMC on coagulation for
periods of hours to days under blood flow. The hemochron tube wall velocity is 0.08
m*min−1, whereas the average blood flow velocity is anywhere from 0.4 m*min−1 in
an artificial lung [21] to 35 m*min−1 in an ECMO cannula [22]. The static setting of
this study results in pooling of reactants, including activated procoagulant molecules
and possibly Cu leaching from the surface into the bulk fluid. In a dynamic system,
both would be washed into circulation, reducing their eﬀect at the biomaterial surface.
2.6 Conclusion
Results from this study indicate that Cu catalyzes NO formation eﬀectively in
silicone-Cu composites, and the NO formation leads to significant inhibition of clot-
ting. Both the NO flux and clotting time depend on the surface copper exposure. At
10 wt%, the clotting time is 4.24 times greater than with pure silicone. Additional
Cu will have diminishing returns, as the surface concentration of copper does not
increase markedly with increasing wt% in this range. Currently we are developing
artificial lungs whose hollow fibers are completely composed of Cu-doped silicone.
These devices will be tested for gas-transfer and for their biocompatibility in vitro
and in vivo respectively.
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CHAPTER III
FABRICATION AND FLUX OPTIMIZATION
OF NITRIC OXIDE-GENERATING HOLLOW
SILICONE FIBERS
3.1 Abstract
Gas exchange fibers represent the majority of the surface area of gas exchange
devices and are thus the primary source of clot generation. In this study silicone
hollow fibers were fabricated to incorporate copper (Cu) particles randomly dispersed
or localized in their walls and evaluated for their ability to produce endothelial levels
of Nitric oxide (NO) flux. Diﬀerent Cu particle sizes (25 nm, 50 nm, and 3 µm) at
10 wt% were dispersed into fiber walls and the presence of Cu on the fibers’ surfaces
were examined using (Phillips XL30FEG) and energy-dispersive X-ray spectroscopy
(EDS) as surface expression of Cu in silicone is necessary for NO generation. Fiber
NO generation via NO donor decomposition were then examined as a function of
Cu particle size. NO generation from 1 cm long fibers (N=5 fibers/ Cu particle
size group) was measured by chemiluminescence with a 280i NO analyzer (Sievers
280i NOA GE, Boulder, CO) using a 1µM S-nitrosoglutathione as the NO-donor in
an aqueous medium (pH = 7.38, 37◦C). The wall thickness of fibers averaged 90 ±
4.4 µm with an average outside diameter of 335 ± 2.1 µm. SEM analysis of fibers’
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surfaces showed the expression of dendritic features that were confirmed to be Cu
by the chemical spectra of EDS. Fibers with 25 nm, 50 nm, and 3 µm Cu particles
randomly dispersed in their walls produced an average peak NO flux of 5.9 ± 0.89,
15.5 ± 3.3, and 3.2 ± 0.5 (x 10−10mol min−1 cm−2) respectively. Those with their
Cu particles localized/concentrated near their outer surfaces produced significantly
higher NO fluxes (9.8 ± 6.8, 29 ± 6, and 48.9 ± 4.3 (x 10−10mol min−1 cm−2)) at the
respective particle sizes (p<0.05). These results indicate that gas exchange fiber can
be modified to generate tunable concentrations of NO at levels comparable to that
produced by the endothelium.
Keywords: Gas exchange fibers, Nitric oxide, Cu(II), and Silicone
3.2 Introduction
The results of work conducted in Chapter II allowed the relationships between
the physical and chemical surface properties of flat silicone membrane and their NO
generation and clotting time to be established. The next logical question was weather
that knowledge can be translated to fibricating gas exchange hollow fibers of artificial
lungs that generates NO? Artificial lungs are used in various respiratory strategies
including extracorporeal membrane oxygenation, arteriovenous CO2 removal, total
artificial lungs, and also in cardiopulmonary bypass (CPB) during cardiac surgery.
Their gas exchange fibers make up the majority of the device surface area and are
made up of polypropylene, polymethylpentene, or silicone. None of these materials
are non-thrombogenic so upon blood contact they adsorb blood proteins, activate
platelets and clot blood leading to increased resistance to blood flow, reduced gas
transfer and thromboembolic complications.
Current methods used to control clotting in gas exchange devices either cause
life-threatening side eﬀects or do not show any clinical benefit in terms of reducing
clotting. Systemic anticoagulation cause bleeding in many patients [1-3] and fiber
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surface coatings such as heparin, trillium, and phosphrylcholine have generally not
shown reduced clotting even during short-term (up to 4h) use in CPB [4-7]. As the
gas exchange fibers represent the majority of device surface area, it’s prudent that
alternative methods for improving device biocompatibility be focused on fibers.
One such alternative that could be applied to gas exchange fibers to improve their
biocompatibility is imparting endothelial-like properties to the fiber’s surface. Nitric
oxide(NO) secretion by endothelial cells is understood as one of the mechanisms that
the endothelium uses to control clotting [8]. NO secretion rate by the endothelium
has been reported to be in the range (1-5) x 10−10mol min−1 cm−2 [9]. Because NO is
lipophilic, the gas can freely cross the lipid bilayer of platelets to indirectly activate
a series of intracellular reactions leading to inhibition of platelet activation [10,11].
Several groups have therefore investigated the functionalization of biomaterials
for either controlled release or generation of NO at physiological fluxes. Both NO
releasing and generation approaches do show positive outcomes in terms of in vivo
inhibition of platelet activation [12]. In a long-term respiratory support however,
NO generation by catalytic decomposition of NO donors will be more suitable for
maintaining better gas exchange as the fiber’s NO production will not be limited by a
finite NO storage capacity. NO production via this approach will continuously occur
for as long as supplied NO donors can interact with catalysts (eg Cu(II)) on fibers.
The catalytic mechanism of NO generation via the decomposition of NO donors by
Cu(II) has already been described in Chapter II.
In this study, hollow silicone fibers are fabricated to incorporate diﬀerent copper
particle sizes as catalysts for generating NO from NO donors. NO flux is evaluated
as a function of particle size. The eﬀect of particle distribution on NO flux and gas
transfer is also presented.
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3.3 Materials and Methods
3.3.1 Preparation of Hollow Fiber Material
The NO-generating polymer was synthesized from a two-part R21-2615 silicone
resin (Nusil Silicone Technology,CA), acetone, and 25 nm, 50 nm, 3 µm copper parti-
cles (Sigma Aldrich Chemical Co. St. Louis, MO). Resins A, B, and acetone solvent
at a ratio of 1:1:0.3 and 10 wt% of Cu at each particle size were systematically mixed
for extruding fibers. To prevent premature cross-linking of resins that may lead to
non-uniform suspension of Cu particles, two separate mixtures were prepared. Resin
A was dissolved into the solvent and Cu particles were suspended in resin B as shown
in Figure 3.1. The two mixtures were separately sonicated for 30 minutes, combined
and sonicated again for 60 minutes to break down aggregates of Cu particles and to
attain a uniform suspension. This step was taken to ensure a uniform distribution of
Cu on the surfaces of fibers. The final mixture was allowed to cross-link under room
temperature for another 60 minutes to increase its viscosity before beginning fiber
fabrication.
Figure 3.1: Synthesis of nitric oxide generating silicone
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3.3.2 Fabrication of NO-generating Hollow Silicone Fibers
Three groups of hollow silicone fibers were evaluated for NO generation. The first
group had randomly distributed particles, the second group of fibers had their Cu
particles concentrated close to their outer surface and the third group did not contain
Cu particles (controls). The fabrication process of the fibers shown in Figure 3.2
centered on incorporating a water soluble polyvinyl alcohol (PVA) supporting rods
(150 µm OD) over which the fibers were extruded. PVA is a non-toxic and environ-
mentally safe polymer that is easily extruded much like polypropylene, and has been
engineered to dissolve in water at any desired temperature. This polymer is used
in applications ranging from pharmaceuticals, food processing, to disposable surgical
gowns. The core adds strength and rigidity to the Cu-doped silicone fibers during fab-
rication and subsequent oxygenator manufacturing. In finished oxygenators however,
this core support would be purged out leaving behind hollow fibers.
Figure 3.2: Fabrication process for nitric oxide generating hollow silicone fibers
The fiber fabrication setup shown in Figure 3.3 consisted of a top guide plate
with a 150 µm aperture (not shown) placed on top of the die to help feed PVA rods
vertically down during extrusion, a 2.5mm-aperture die containing a reservoir into
which coating materials are loaded, and a bottom guide plate (aperture size = 350
µm) placed beneath the die to regulate the final outside diameter of fibers. This
fabrication setup is a modified benchtop replica of that used by Medarray Inc. PVA
rods were hand-fed at 12 inches/min and emerged coated at the opposite end of the
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die. Coated rods were immediately cured at 500◦F.
Figure 3.3: Extrusion setup for nitric oxide generating hollow silicone fibers
Control fibers and fibers with randomly dispersed Cu particles were fabricated by
passing naked PVA rods through the die once. Fibers with particles localized close to
the outside walls were fabricated to have a double layered (DL) structure. The PVA
rods were first coated with pure silicone to a finite thickness using a bottom guide
plate with a 250 µm aperture. After curing, a second 50 µm silicone layer containing
appropriate Cu amounts was coated over the first and then cured.
3.3.3 Characterization of Fiber Structure and Wall Surface
To examine fiber-to-fiber cross section and wall thickness uniformity, all fibers were
imaged with a Philips XL30 FEG scanning electron microscope. As NO generation
from Cu-doped silicone depends on surface Cu, the extruded fibers were characterized
for the presence of Cu on their surfaces. The presence of Cu on the fibers was
verified with energy dispersive x-ray spectroscopy (EDS) (EDAX Inc. Mahwah NJ).
Specifically, sections of the extruded fibers (N=5, 1 cm long per fiber group) were
analyzed with EDS. The following settings were used during the EDS analysis: input
count rate = 1000cps, energy resolution = 135eV, peak/background = 100, and the
scanned surface area = 4 mm2.
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3.3.4 Measurement of Nitric Oxide Generation from Fibers
NO generation from fibers were measured by gas-phase chemiluminescence as de-
scribed in Chapter II. Specifically fibers (N = 5/1 cm long per fiber group) were in-
troduced into a 1 µM S-nitrosoglutathione (GSNO) to activate a chemiluminescence
reaction and the peak NO flux was measured with a nitric oxide analyzer (Sievers
280i NOA GE, Boulder, CO). NO generation was measured for at least 30 minutes
from each sample.
3.3.5 Statistical Analysis
One-way ANOVA was performed to compare the dependent variable, NO flux,
using the weight percent of copper and copper distribution inside fiber wall as the in-
dependent variables. A p-value < 0.05 is regarded as significant. All data is expressed
as mean ± standard deviation.
3.4 Results
3.4.1 Structure and Surface of Hollow Silicone Fibers
All fibers tested in this study showed uniform cross section and and wall thicknesse.
As shown in Figures 3.4A and 3.4B, their wall thickness averaged 90 ± 4.4 µm and
outside diameter averaged 335 ± 2.1 µm. Also the cross section of fibers fabricated
to concentrate their Cu particles close to their outer surface is shown in Figure 3.4C.
The area between the broken concentric circles (t = 50 ± 10 µm) is the first layer
void of copper particles and the outer layer (t = 55 ± 15 µm) contained Cu particles.
The surface morphology of Cu-doped fibers were similar to that of Cu-doped
silicone membranes presented in Chapter II. As shown in Figure 3.5 their surface
morphology showed dendritic structures that were evenly distributed on their outer
surfaces. Figure 3.5A is a low magnification view representative of 10 wt% Cu-doped
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Figure 3.4: Extruded NOgen fibers showing cross section A)and outer surface of fibers
B) of fibers with randomly distributed Cu, and cross section of fibers with
their Cu concentrated towards their outer surface C).
fibers. Close inspection of fibers (Figure 3.5B) by magnifying the area highlighted
in Figure 3.5A, revealed features similar to those found in previous studies where
Cu particles were doped into silicone membranes. The chemical map of the fibers’
surface shown in Figure 3.5C and the chemical spectra in Figure 3.5D confirmed the
dendritic features to be Cu particles. The presence of carbon, oxygen, and silicone
which make up the base polymer were also confirmed.
Figure 3.5: A representative surface morphorlogy and chemical composition of NO-
gen hollow silicone fibers. The SEMs of the fiber is shown in a) and in
b) at a higher magnification. The elemental map on the surface of the
fiber showing Cu dendrite expression on silicone is shown in c) and the
elemental spectra in d).
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3.4.2 NO Generation from Hollow Silicone Fibers
A representative nitric oxide generation profile from fibers using methods de-
scribed in section 3.3.4 is shown in Figure 3.6. All fibers tested showed a similar pro-
file where NO generation only began after the fiber was introduced into the GSNO
solution. The level of NO flux return back to pre-sample introduction levels after
GSNO was consumed. The average peak NO flux from randomly distributed 25 nm,
50 nm and 3 µm Cu fibers is shown in Figure 3.7.
Figure 3.6: Representative profile of nitric oxide generation from Cu-impregnated sil-
icone hollow fibers. Fibers were bathed in 1 µM GSNO at 37◦C for NO
detection by chemiluminescence.
As summarized in Table 3.1, all the fibers produced NO fluxes comparable to
physiological levels. NO flux produced from the 50 nm Cu particle fibers (15 ± 4 x
10 −10 mol cm−2 min−1) was significantly higher than those produced from the 25 nm
Cu particle fibers (6 ± 1 x 10 −10 mol min−1 cm−2) and the 3 µm Cu particle fibers
(3 ± 0.6 x 10 −10 mol min−1 cm−2), p<0.01.
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Table 3.1: Nitric oxide (NO) flux levels from hollow silicone fibers
Copper particle size Fiber structure Peak NO flux
(average diameter) (Single/Double layer) (x10−10 mol min−1
cm−2)
— Single 0
25 nm Single 5.9 ± 0.89*
√
Double 9.8 ± 6.8*
50 µm Single 15.5 ± 3.3**
√
Double 29 ± 6**
3 µm Single 3.2 ± 0.5*
√
Double 48.9 ± 4.3***
* : p<0.05, ** : p<0.01, *** : p<0.001 significance from control
Figure 3.7: Peak nitric oxide flux from hollow silicone fibers impregnated with diﬀer-
ent sizes of Cu particles
NO flux from DL fibers having wall structures similar to that shown in Figure 3.5C
further increased significantly compared to fibers with random dispersion of Cu. Their
peak flux levels are shown in Figure 3.8. The clear bars are the same data shown in
Figure 3.7 which represent the NO flux levels from single layer fibers and the dark
bars are flux levels from double layer fibers. The dark bars show significantly larger
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(p < 0.05) NO flux levels than their clear counterparts in the 3 µm and 50 nm Cu
particle groups. Such significance level was however not seen between the double and
single layer fibers of the 25 nm Cu particle group. In general fibers with random
dispersion of Cu showed higher fluxes with smaller Cu particles.
Figure 3.8: Peak nitric oxide flux from hollow silicone fibers with diﬀerent Cu distri-
bution and particle sizes .
3.5 Discussion
The results show that Cu particles can be incorporated into hollow silicone fibers
during fabrication to impart NO generating property to the fibers. NO fluxes pro-
duced by these fibers were greater than physiological production levels. Fibers that
had randomly dispersed Cu particles showed flux levels ranging from (3 ± 0.6 to 15.5
± 3.3) x 10 −10 mol min−1 cm−2. When the Cu particles were localized at fibers’
surface, even higher NO fluxes were observed. Their NO flux ranged from (9.8 ±
6.8 to 48.9 ± 4.3) x10−10 mol min−1 cm−2. As discussed in Chapter II, greater NO
production was possible in the double layer fibers because all the Cu particles were
dispersed in the second layer of the fibers allowing for a higher concentration of Cu
close to their surfaces. Essentially, the amount of Cu in the second layer was 10 wt%.
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However, with respect to the total fiber composition, the amount of constituent Cu
equals 5 wt%. Therefore the amount of total Cu in the double layer fiber could be
as small as half of that in the double layer fibers. Yet, greater amounts of NO pro-
duction was measured in the single layer fiber group indicating that lesser wt% Cu is
capable of generating physiological levels of NO flux and might better maintain the
gas permeability of the membrane.
NO generation from these fibers during blood flow through gas exchange devices
will depend on availability of NO donors. Physiological NO donor concentrations
range from nanomolar to micromolar levels [13] and maybe inadequate for sustained
NO production. Exogenous NO donors may have to be supplemented into blood in
order to sustain NO production. In fact this method of sustaining continued gener-
ation of NO has been published in work involving NO generation via Cu mediated
nitrosothiol decomposition from Cu-coated extracorporeal circulation (ECC) circuits
[14].
The problem of leaching in blood-contacting surfaces coated with commercial anti-
clotting agents during blood flow is also present in membranes impregnated with Cu
particles. Leached Cu from Cu-coated ECC circuits after 4hrs of blood flow has been
reported to rise from normal serum copper concentration of 134.7 ±22.5 µg/dl by
two fold. This level of leaching is still well below the food and drug administration’s
acceptable serum copper concentration of 750 µg/dl. Leaching levels from NO gener-
ating fibers is unknown and can be better evaluated when they are incorporated into
gas exchange devices.
The inclusion of Cu particles in fibers may also influence their gas transfer to a
magnitude corresponding to the finite amount of fiber’s surface area taken up by Cu.
Secondary flows due to fibers’ orientations inside fiber bundles of gas exchange devices
may counter any diminutive eﬀect that Cu particles might have on gas transfer. The
gas transfer of NO generating fibers must be determined and will be best evaluated
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after incorporating them into gas exchange devices.
3.6 Conclusion
Incorporation of Cu particles into hollow silicone fibers during fabrication imparts
NO generating property to the fibers. These fibers containing 10 wt% Cu either
randomly dispersed in their wall or concentrated in their outer half of their walls
showed higher than physiological levels of NO flux. Concentrating Cu particles in the
outer half of the fiber’s wall at least doubles NO production.
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CHAPTER IV
DEVELOPMENT AND BIOCOMPATIBILITY
TESTING OF NITRIC OXIDE-GENERATING
HOLLOW FIBER ARTIFICIAL LUNG
4.1 Introduction
In Chapter III, we learned the following: Cu incorporation into gas exchange
fiber walls lead to NO generation, smaller particle sizes of Cu at the same wt% yield
higher NO flux levels, and localization of Cu particles close to outer surface of fibers
increases NO flux levels. This knowledge was applied to the development of the first
NO-generating artificial lung. Thrombogenicity testing of NO generating surfaces
has been studied in the past, but only in large-bore high-flow and low surface area
ECC circuits and never in artificial lungs with low flows and high surface areas. A
single-layer fiber structure and 50 nm Cu particles were employed for developing
the artificial lung because of manufacturability and the fact that the highest NO
generation from fibers fabricated in the previous chapter was observed in single layer
fiber group containing 50 nm Cu particles.
NO generating artificial lungs require evaluation in terms of their inhibition of clot
formation as current artificial lung solutions for clot reduction, although decades old,
have not worked without some form of clotting complication or bleeding in patients
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requiring respiratory support for reasons including lung diseases. About 400,000
Americans die from lung diseases such as acute respiratory distress syndrom (ARDS),
chronic obstructive pulmonary disease (COPD), cystic fibrosis and bronchopulmonary
dysplasia every year [1]. Mortality rates in ARDS patients alone range from 25 - 40%
of 190,000 Americans aﬄicted with the disease each year. Also 4.2% COPD patients
in America do not survive the disease per year. The only treatment for these diseases
in their end-stage conditions is transplantation, but unfortunately the limited pool of
available donor lungs makes it impossible to treat all patients. As a result about 300
patients waitlisted for lung transplantation loose their lives before treatment every
year [2]. Bridge-to-lung transplantation strategies like total artificial lung (TAL),
arteriovenous CO2 removal (AVCO2R) and extracorporeal membrane oxygenation
(ECMO) are able to provide respiratory support for these patient population only for
a couple of weeks without replacement of their gas exchange devices. New methods
intended for reducing clot formation inside artificial lungs may lead to fewer device
replacement, and thus extend the functional lifespan of the artificial lung. Patient
populations given short-term respiratory support, without systemic anticoagulation
or with a limited use of it, can also benefit from devices that remain clot-free during
long-term use.
The gas exchange materials of these respiratory support devices are capable of
modifying venous blood to arterial conditions by providing oxygen and removing
CO2 [3-6]. However, none of these fibers are suﬃciently biocompatible to allow a
single device to be used for more than two weeks to one month. Their contact with
blood can lead to clotting complications, and poor gas exchange [7-10]. For example,
the MC3 Biolung when used as a TAL showed a 300% increase in resistance from
baseline, and warranted device repalcement, on average, every 9.5 ± 2.1 days [11]. In
addition, clot shedding led to ischemic regions in the kidney. Membrane lungs with
antithrombotic coatings are available,[12-16] but unfortunately the coatings have not
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worked well enough to eliminate the frequent device replacement due to clot formation
or eliminate the need for systemic anticoagulation.
In this work NO generation artificial lungs were fabricated by modifying their
gas exchange silicone fibers with Copper. Copper (Cu) particles dispersed in their
gas exchange fiber walls catalyze circulating s-nitrosothiols to generate NO locally
as shown in Figure 4.1 [17-19]. The NO generating artificial lung was inserted into
an extracorporeal circulation (ECC) circuit that was similarly coated with the NO
generating material, and the circuit was evaluated for their thrombogenicity during
a 4 h ECC in rabbits
Figure 4.1: Model of Cu-mediated NO generation from circulating S-nitrosothiols by
hollow fiber membrane lungs for platelet inhibition
4.2 Materials and Methods
4.2.1 Design of NO-Generating Hollow Silicone Fiber Oxygenator
A radial flow artificial lung design was constructed with NO generating or non-
NO generating silicone hollow fibers. NO generating fibers were doped with 50 nm
Cu particles at 10 wt% and non-NO generating fiber had no Cu. In the radial flow
design, blood flows through an annular hollow fiber bundle (see Figure 4.2). This
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design constraints blood to flow radially outward through the fiber bundle thereby
reducing shunting or channelling across the bundle, thus ensuring blood perfusion
throughout. Blood enters the device through the bottom inlet and flows within a
1/4” polyester bundle core serving as a central passageway oriented along the axis of
the fiber bundle. Blood is then directed radially outward through the bundle driven
by a pressure diﬀerence between the central core and an outer passageway or gap
between the outside of the bundle and the oxygenator housing. Blood is collected
and oriented toward the oxygenator outlet(s) at one side of the oxygenator. The
fiber bundle porosity of all NOgen prototypes (% of volume occupied by blood in the
bundle over total volume of the bundle) were fixed at 10%.
Standard hollow fiber oxygenator fabrication methods were used to manufacture
the NO-generating lungs at Medarray Inc.
Figure 4.2: Design of radial flow ECMO oxygenator (Borrowed with permision from
Medarray Inc).
In brief, a spool of NO generating and non-NO generating fibers were woven into
a mat with an industrial capacity knitter. The fiber mats were then rolled over the
meshed cylindrical polyester bundle core. This bundle assembly was potted within
a polycarbonate housing inside an 80 Gs centripetal force centrifuge. The potted
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devices were then purged of their PVC fiber cores using a constant flow of water jet
(25 Psi, 70 ◦C). All devices were then leak teasted as they underwent an aggressive
purging process during PVA core romval. Defective fibers demonstrating water leaks
were plugged at both ends with polyurethane. Gas flow end caps were then attached
at the ends of each device (see Figure 4.2) to have them ready to be incorporated
into extracorporeal circulation circuits (ECCs).
4.2.2 ECC Circuit Components
The ECC circuit is an arterio-venous (AV) shunt shown in Figure 4.3. From the
inlet to the outlet, it consisted of a 16 gauge angiocath, 1/4” luer lock PVC connec-
tor, 3” long 1/4” ID tygon tubing, a 1/4” - 1/4” luer lock straight polycarbonate
connector, 3” long 1/4” ID tygon tubing, the artificial lung (SA = 0.09 m2), and
1” and 2” long 1/4” ID tygon tubings connecting to a 1/4” - 1/4” - 1/4” Y poly-
carbonate connector, 3” long 1/4” ID tygon tubing, a 1/4” - 1/4” leur lock straight
polycarbonate connector, 1/4” leur-lock PVC connector, and a 14 gauge angiocath
all connected in series. The NO generating shunts were coated tip-to-tip with our
NO-generating material (50 nm Cu particles in silicone) following the same synthesis
procedure described in Figure 3.1. The tygon tubing were however diﬃcult to coat
with silicone. Therefore, small pieces of tubing were dissolved in THF (1g per 3mL
THF), and then the Cu nano particles were blended into the dissolved material. The
resin were then coated onto the tubing. All coated tubing sections were cured under
ambient temperature for 48 hours. The NO-generating and control shunts are shown
in Figures 4.3B and 4.3A respectively.
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Figure 4.3: Extracorporeal circulation circuits: Control (clear) and NO-generating
(bottom)
4.2.3 Measurement of NO Flux from Fibers
NO generation were measured from 1 cm long tubing samples (N = 5/NO generat-
ing and non-NO generating surfaces), and from 1 cm long fibers (N=5/NO generating
and non-NO generating type) using the same NO measurement techniques described
in section 3.3.4 of Chapter III. In brief, NO released from the surface was measured
through a chemiluminescence reaction using a Seivers nitric oxide analyzer (NOA),
model 280 (Boulder, CO). A nitric oxide donor, S-nitrosoglutathione (GSNO) was
first prepared by reacting equimolar glutathione (GSH) and NaNO2 in 0.06 M H2SO4.
Next, the GSNO (1 µM), 30 mM GSH and 5 mM EDTA were added to an amber re-
action vessel containing phosphate-buﬀered saline (PBS, pH= 7.34) at 37 ◦C. EDTA
was used to chelate any trace metal ions that may be present in the solution. The
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solution was then purged with nitrogen gas and the output gas was swept to the NOA
through an air-tight sampling line at 200 ml/min. Baseline measurements were taken
for 5 minutes before samples were introduced into the GSNO rich solution. The NO
generated from the reaction between Cu ions and GSNO was continuously swept to
the NOA and recorded over time. Inside the NOA, the NO content in the output
gas is reacted with ozone to produce oxygen and a high energy unstable NO gas. To
achieve a thermodynamically stable state, each unstable NO molecule releases a pho-
ton which is counted to measure the concentration of NO produced by the samples.
NO concentration was continuously measured, and a peak NO flux was calculated by
dividing the sample surface area into the peak rate of NO generation.
4.2.4 Rabbit Thrombogenecity Model for Testing ECC Circuits
The animal handling and surgical procedures were approved by the University
Committee on the Use and Care of Animals in accordance with university and federal
regulations. A total of 10 ECC circuits (N=5/group) were tested for thrombogenecity
using 10 adult New Zealand male rabbits (Myrtle’s Rabbitry, Thompson’s Station,
TN). All rabbits (2.5-3.5 kg) were initially anesthetized with intramuscular injections
of 5 mg/kg xylazine injectable (AnaSed Lloyd Laboratories Shenandoah, Iowa) and
30 mg/kg ketamine hydrochloride (Hospira, Inc. Lake Forest, IL). Maintenance anes-
thesia was administered via a diluted intravenous (IV) infusion of ketamine (2 mg/ml)
at a rate of 1.53 mg/kg/hr. In order to maintain normal blood pressure, Lactated
Ringers solution was given at a rate of 33 ml/kg/hr. A tracheotomy was performed
with a 5mm OD trach tube, and the rabbit was placed on a Sechrist Infant Ventilator
Model IV-100 (Anaheim, CA). The paralytic, pancuronium bromide (0.33 mg/kg,
IV), was then administered to ensure that the rabbit would not over-breathe the ven-
tilator. For monitoring blood pressure and collecting blood samples, the rabbit right
carotid artery was cannulated using a 16-gauge IV angiocatheter (Jelco R￿, Johnson
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and Johnson, Cincinnati, OH).
Blood pressure and derived heart rate were monitored with a Series 7000 Monitor
(Marquette Electronics Milwaukee, WI). Body temperature was monitored with a
rectal probe and maintained at 37◦C using a water-jacketed heating blanket. Prior
to placement of the AV ECC shunt, the rabbit left carotid artery and right external
jugular vein were isolated, and hemodynamic data was recorded. Arterial blood
pH, pCO2, pO2, total hemoglobin and methemoglobin were then measured using
an ABL 725 blood gas analyzer and OSM3 Hemoximeter (Radiometer Copenhagen
Copenhagen, DK). In addition, baseline blood samples were collected for platelet
and total white blood cell (WBC) counts utilizing a Coulter Counter Z1 (Coulter
Electronics Hialeah, FL), plasma fibrinogen levels measured by a Dade Behring BCS
Coagulation Analyzer (Siemans Deerfield, IL), activated clotting time (ACT) using
a Hemochron Blood Coagulation System Model 801 (International Technidyne Corp.
Edison, NJ) and platelet aggregation using a Chrono-Log optical aggregometer model
490 (Havertown, PA).
The ECC was primed with saline solution and 6U/ml of heparin sulfate and placed
into position by cannulating the left carotid artery for ECC inflow and the right
external jugular vein for ECC outflow. Blood flow through the ECC was started
by unclamping the arterial and venous sides of ECC and blood flow in circuit was
monitored with an ultrasonic flow probe (1/4” ME6PXN) and flow meter (Tran-
sonic HT207 Ithaca, NY). The rabbits were then given a heparin bolus (300U/kg,
IV) followed by a 10U/kg/hr heparin infusion to maintain ACTs between 350-400
seconds. In addition, 0.1182 µmol/kg/min infusion of the NO donor, S-Nitroso-N-
acetylpenicillamine (SNAP), was started immediately after the ECC blood flow was
initiated. After four hours on ECC plus either saline or SNAP infusion, the circuits
were clamped, removed from animal, gently rinsed with 60 ml of saline and drained.
Any residual thrombus in the larger tubing of ECC (i.e., thrombogenicity chamber)
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was photographed. All rabbits then received a dose of 400 U/kg sodium heparin to
prevent necrotic thrombosis, were euthanized with Fatal Plus (130 mg/kg sodium pen-
tobarbital; Vortech Pharmaceuticals Dearborn, MI), and underwent gross necropsy
to examine the lungs, heart, liver and spleen for any signs of thromboembolic events.
4.2.5 Blood sampling
Rabbit whole blood samples were collected in non-anticoagulated 1 cc syringes for
ACT, 10% anticoagulant containing sodium citrate, sodium phosphate and dextrose
(ACD) (Hospira,Inc. Lake Forest, IL) in 3 cc syringes for cell counts, aggregometry
and FACS analysis and 1 cc syringes containing 40 U/ml of sodium heparin (APP
Pharmaceuticals, LLC Schaumburg, IL) for blood gas analysis. Every hour up to 4
hours, following the initiation of ECC blood flow, blood samples were collected for
in vitro measurements. Samples were used within 2 hours of collection to avoid any
artifactual activation of platelets, monocytes or plasma fibrinogen.
4.2.6 Plasma Fibrinogen
Plasma fibrinogen plays an important role in clot formation as it forms intercon-
necting bridges for platelet adhesion. Soluble fibrinogen concentration in control and
NOgen ECC circuits plasma samples were measured at baseline and every hour for 4
hours using a BCS XP System hemostasis analyzer (Siemens Healthcare Diagnostics,
Deerfield, IL). Briefly, lyophilized bovine thrombin (Dade Behring, Deerfield, IL) was
prepared according to Dade thrombin reagent kit instructions and added to plasma
samples. The clotting time of plasma (time taken to convert soluble fibrinogen into
insoluble fibrin), inversely proportional to fibrinogen concentration, was measured
with the BCS XP System and then compared to that of standardized fibrinogen
concentrations of human plasma (Chrono-Log Corp. Havertown, PA).
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4.2.7 Platelet aggregometry
Rabbit platelet aggregation was assayed based on Born’s turbidimetric method
using a Chrono-Log optical aggregometer. The method used was previously described
[23]. Briefly, citrated blood (1:10 blood to ACD) was collected (6 mls) and platelet-
rich plasma (PRP) was obtained by centrifugation at 110 x g for 15 min. Platelet-poor
plasma (PPP) was obtained by another centrifugation of the PRP-removed blood
sample at 2730 x g for 15 min and was used as the blank for aggregation. PRP
was incubated for 10 min at 37◦C and then 40 mg/ml collagen (Chrono-PAR #385
Havertown, PA) was added. The percentage of aggregation was determined 3 min
after the addition of collagen using Chrono-Log Aggrolink software.
4.2.8 Measurement Plasma Copper
The in vitro plasma copper assay (DICU-250, Gentaur, Accurate Chemical &
Scientific Corporation New York, NY) was performed in a 96-well format to determine
the amount of copper leaching from the ECC over the 4 hour experimental period.
Briefly, both baseline and 4 hour plasma samples were treated with 30% trichloroacetic
acid. Samples were centrifuged at 14,000 RPM for 5 minutes and 100 µl of the
supernatant was collected. Each sample was diluted 1 : 2 with deionized water
and 100 µl placed in a 96-well plate. A copper standard (1.5 mg/dl CuSO4) was
serial diluted and 100 µl of each concentration, ranging from 0-300 µg/dl, was placed
in separate wells. A working reagent mix containing 0.9% ascorbic acid, 0.1% 4,4-
Dicarboxy-2,2-biquinoline, 2% NaOH and 8% Hepes-free acid was then added to each
well of the 96-well plate and then mixed. After a 5 minute incubation, absorbance
measurement of the plate was performed at 359 nm on a Synergy 2 microplate reader
(Biotek Winooski, VT). All measurements were done in duplicate. Using a linear
regression curve from a copper standard (0-300 µg/dl), sample copper concentrations
were calculated.
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4.2.9 Measurement of Blood Flow Resistance
To monitor blood flow resistance inside artificial lung prototypes, real time pres-
sure drop across the devices was measured with a Biopac MP150 data acquisition
system (Linton Instrumentation, UK). Briefly, primed line pressure transducers (Hos-
pira Inc. Lake Forest, IL) were connected to the device’s inlet and outlet stopcocks
(see Figure 4.3). The pressures were recorded at the onset of blood flow, at every
5 minutes during the first hour of flow, and at every 30 minutes for the 4 h test
duration. Resistance to blood flow inside the device was calculated as the pressure
drop (mmHg) across the device devided by blood flow rate (ml/min).
4.2.10 Statistical Analysis
The statistical program, SPSS, was used to analyze significance in means of out-
comes data. Mixed model analysis with repeated measures was used to compare
dependent dependent variables (platelet count, plasma fibrinogen, and blood flow
resistance) between subjects (10 wt% of NOGen and control ECC circuits). Time
eﬀects on dependent variables were analyzed within groups. A p-value < 0.05 is
regarded as significant.
4.3 Results
4.3.1 NO generating Artificial Lung Prototype and their NO generation
The prototype of nitric oxide generating hollow silicone fiber oxygenator is shown
in Figure 4.4. As briefly described in oxygenator design phase (section 4.2.1), blood
enters the device through the blood inlet conduit, radially flows around the NO-
generating hollow fibers and exits through the two outlet conduits on the side of the
device. Gas also flows into the device through the gas inlet, then through the hollow
fibers and exits through the gas outlet. Its path length is about 1.1 cm and the axial
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length is about 2.7 cm. The fiber packing fraction is 0.33. All NO-generating lungs
as well as controls had a prime volume of 20 cc and a total membrane surface area
of 0.09 m2. The gas exchange silicone fibers of the NO-generating lung, as opposed
controls, appear dark due to the copper nanoparticles incorporated into their walls.
Figure 4.4: Prototype of nitric oxide generating hollow silicone fiber oxygenator
4.3.2 NO Flux from Fibers
The NO flux from 10 wt% 50 nm Cu particle doped fibers and coated ECC tubing
were (12 ± 4 and 14.7 ± 2.5) x 10 −10 mol cm−2 min−1 respectively. Their control
counterparts showed no NO release.
4.3.3 Survival of NOgen and Control ECCs
The Kaplan-Meier survival for flow in control and NOgen ECC circuits is shown
in Figure 4.5. All NOgen ECC circuits stayed patent for the entire test duration.
In contrast, after 30 minutes of blood flow initiation, 2 control ECC circuits totally
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occluded stopping flow and thus ending their thrombogencity test. Another control
ECC circuit occluded after 60 minutes. On the other hand, all N = 5 NOgen ECC
circuits were stayed patent at the during the 4-hour test period.
Figure 4.5: Survival of control and experimental ECC circuits after flow initiation.
During ECC, the resistances within the circuits were monitored to further evaluate
thrombogenic diﬀerences in NOgen and control groups. The in-vivo average resistance
results of control and NOgen ECC circuits are discussed in detail in section 4.3.6.
4.3.4 Thrombogenecity Outcomes
Platelet consumption, plasma fibrinogen concentration, and copper leached into
plasma over the course of the experiment is shown in Figures 4.6, 4.7 and 4.9 respec-
tively.
Platelet consumption: The preservation of platelets during any blood-contact ap-
plication is one of the evaluational parameters for determining the overall thrombo-
genecity of the application/biomaterial. Platelet preservation as measured with a
Coulter counter in terms of the concentration of platelets in circulation on an hourly
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basis showed a general decline. This method of evaluating platelet preservation ba-
sically compared baseline to post-baseline platelet concentrations to determine how
many platelets were lost to adhesion and adsorption. This method is insensitive to
the state of aggregation and location of adsorption.
Figure 4.6: ECC circuits’ platelet consumption during blood flow.
It is important to note in Figure 4.6 that only an N=2 control ECC circuits
survived the 4 h test duration. The remaining 3 circuits clotted oﬀ within an hour.
Hence the use of mixed model analysis to better determine significance in outcomes.
In both control and NOgen ECC groups, platelet counts dropped significantly (p
< 0.05) from baseline to 58.3 ± 5.6% and 53.5 ± 4.3% respectively after an hour
of extracorporeal circulation. The eﬀect of wt%Cu on platelet count approached
significance (p=0.055), but a larger N size (>5) may reveal it’s true eﬀect. In the test
duration, there was no time eﬀect, as a function of wt%Cu, on platelet count within
groups (p>0.05).
Plasma fibrinogen: The time-course concentration of plasma fibrinogen as shown
in Figure 4.7 indicate the conversion of fibrinogen into fibrin. After 1 hour on ECC,
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there was a significant reduction in plasma fibrinogen from baseline in both control
and NOgen circuits (p < 0.01). The intra-group time-dependent fibrinogen level
remained unchanged after an hour (p < 0.01) in both groups. However there was a
significant diﬀerence between the inter-group time-dependent fibrinogen levels (p <
0.05). In the NOgen ECC circuits more fibrinogen was polymerized than in controls
perhaps due to increased fibrinogen attraction to and activation at a more charged
and irregular surface. No time eﬀect, as a function of wt%Cu, on plasma fibrinogen
concentration was observed (p=0.24).
Figure 4.7: Levels of plasma fibrinogen concentration during extracorporeal circula-
tion
The total surface area contacted by blood is also a relevant assessment parameter
for thrombogenecity of ECC circuits because 1) blood activation and coagulation is
both time and surface sensitive and 2) a fair comparison can still be made between
diﬀerent ECC groups regardless of group survival. As shown in Figure 4.8 there was
a drastic diﬀerence in total surface area contacted by blood in the control and NOgen
ECC groups. The total blood-contacted surface area in control group is significantly
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smaller than the NOgen group after 30 minutes of ECC (p < 0.05).
Figure 4.8: Time course of blood flow
The diﬀerence was even more significant (p < 0.001 ) at 4 hours of circulation
since all 5 NOgen and only 2 control ECC circuits maintained flow. Taken together,
the Kaplan-Meier survival, platelet consumption and total-blood-contacted surface
area data indicate worse thromboses in the control ECC circuits. In general, less
blood contact with a biomaterial due to clotting leading to stopage of blood flow
through an ECC circuit also implies no platelet consumption. Therefore for the
control and NOgen ECCs to have comparable platelet consumption but significantly
diﬀerent total-blood-contacted surface area due to increased resistance and stopage
of flow in controls means the state of platelet activation/aggregation was diﬀerent in
both groups.
4.3.5 Plasma Copper Concentration:
Plasma copper concentrations measured during extracorporeal circulation through
the NOgen circuits is shown in Figure 4.9). Serum copper levels at the onset of blood
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flow in control group (132.8 ± 4.5 µg/dl) and NOgen group (134.7 ± 22.5 µg/dl)
were not significantly diﬀerent (p < 0.01). They were also about 6 fold lower than
the acceptable daily copper intake for adults. As expected baseline copper levels was
maintained after 4 hours (p < 0.01) in the control group. However, plasma copper
levels in the NOgen group significantly (p < 0.001) increased from baseline by 2.8
folds.
Figure 4.9: Levels of plasma copper at baseline and at the end of extracorporeal
circulation
4.3.6 ECC Blood Flow and Artificial Lung Resistance
Comparisons of the intra-group and inter-group time-dependent average resistance
were made to determine diﬀerences between ECC circuit groups and within groups.
The resistance in the NOgen circuits (black bars) and control circuits (white bars) is
shown in Figure 4.10. At the onset of ECC blood flow, the resistances in the controls
(0.08 ± 0.06 mmHg min/mL) and NOgen ECC circuit (0.05 ± 0.02 mmHg min/mL)
were not diﬀerent (p < 0.05). These values were consistent with pre-ECC resistance
measurements with water flow. Also, there was no diﬀerence in the time-dependent
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resistance from baseline within the NOgen group after 4 hours of ECC (p < 0.01). In
the Control group, post baseline resistance were all significantly higher than baseline
resistance (p < 0.01). After 30 minutes of ECC, the resistance of the control group
was significantly higher (21 ± 9 mmHg min/mL, p < 0.01) than that of the NOgen
group (0.07 ± 0.02 mmHg min/mL). This diﬀerence in significance is also maintained
through out the rest of the experimental time.
Figure 4.10: Time course of control ECC resistance to blood flow
As shown in Figure 4.11, there was no diﬀerence between baseline blood flow
in control (63.6 ± 8.04 mL/min) and in NOgen (70.2 ± 28.1 mL/min) circuits at
baseline (p = 0.62) indicating similar cardiac function in rabbit populations used
in both groups. The dramatic diﬀerences seen after baseline is a not a function of
cardiac output but rather the diﬀerences in inter-group ECC resistance represented
in Figure 4.10. In the NOgen group, flow was stable during the entire experiment.
There was no significant diﬀerence in baseline and post-baseline flows within the
NOgen ECC group (p = 0.07). However in the control group, post-baseline flow were
significantly lower than baseline flow (p < 0.01).
114
Figure 4.11: Time course of blood flow
The time-course ECC resistance and flow clearly show a dramatic diﬀerence be-
tween the NOgen circuit group and the control group. The NOgen group maintained
baseline flows and resistance during the 4 hour study. These parameters have an im-
portant eﬀect on organ perfusion and heart function during extracorporeal membrane
oxygenation in general. In pulmonary artery - left ventricle ECMO attatchment mode
for instance, the right heart can failure due to loading from highly resistive circuits.
In addition limited blood flow to organs can cause hypoxia and irreversible organ
damage.
4.4 Discussion
The aim of this study was to develop a copper mediated NO-generating hollow
fiber membrane lung and evaluate its non-thrombogenicity in an extracorporeal cir-
culation set up. The results indicate that the NO-generating ECC circuits were less
thrombogenic than their non NO-generating controls.
Nitric oxide generation from NOgen circuits was controlled against non-NO gen-
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erating circuits. The NO flux from 10 wt% Cu NOgen fibers and 10 wt% Cu coated
PVC tubings making up the NOgen circuit were 12 ± 4 x 10 −10 mol cm−2 min−1 and
14.7 ± 2.5 x 10 −10 mol cm−2 min−1 respectively. These levels of NO flux produced
by the NOgen ECC circuits have been previously shown to reduce thrombogenecity
[24], and are also higher than levels produced by the endothelium. The importance
of copper expression on the surface of silicone for eﬃcient NO generation has already
been described in section 3.5. Briefly, Cu-mediated NO generation at the surface
of silicone requires a physical interaction between RSNOs and Cu ions produced by
Cu corrosion at the polymer’s surface. The eﬀect of surface exposure of copper on
NO flux is demonstrated in Chapter II, and was important for NO generation from
Cu-doped silicone fibers.
NO generating ECC circuits group were patent for the duration of the study while
the survival of control circuits dropped to 40% after an hour of circulation. The mod-
ified ECC circuits also showed significantly lower resistance compared to the control
group. Resistance in control circuits were, on average, almost two orders of magni-
tude larger (x 87.4) than that in the NO generating group. Accordingly, flows in the
control group was significantly lower than the NOgen group after baseline. Larger clot
formation in the control increased their resistance to flow and subsequently occluded
the devices. Platelet consumption in the ECC groups as measured with a coulter
counter interestingly showed insignificant diﬀerences between the groups. This piece
of data is contradictory to the global thrombogenicity diﬀerences observed between
the groups. This contradiction is due to the fact that the coulter counter method for
measuring platelet proved insensitive to the degree of platelet aggregation. It mea-
sures platelet concentration by counting flowing platelets through a 3 - 4 µm gated
channel specific to the size of a single platelet. Any body bigger in diameter is not
counted. It is therefore possible to measure a 50% drop in platelet count for two
diﬀerent samples; one with aggregates of two platelets per aggregate and the other
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with massive aggregates. However these two states of aggregation will have very dif-
ferent physiological eﬀect as low levels of activation lead to more transient responses.
This insensitivity in detecting low level aggregation can obscure diﬀerences in aggre-
gation degrees and thrombogenecity evaluation as evident in the control and NOgen
groups. In the NOgen ECC group, these platelet microaggregates are prevented from
growing into macroaggregates because of the anesthetic eﬀect of nitric oxide being
generated at the blood/polymer interface. That was why their circuit resistance and
flow remained at baseline levels through out the experiment.
The results also indicate that plasma fibrinogen is lost to the NOgen environ-
ment more than in controls. The decrease in fibrinogen adsorption perhaps is due to
a rougher blood/NOgen polymer interface owing to surface copper particles or due
to a stronger charge interaction between the polymer surface, where an oxidation-
reduction reaction is constantly taking place, and the polar terminals of plasma fib-
rinogen in flowing blood. The mechanisms of interaction among the NOgen surface,
NO generation and fibrinogen activation is however still not clear [24].
Blood activation and subsequent coagulation on biomaterials depends on duration
of exposure and other factors. When the duration of exposure is expressed in terms of
total blood contacted surface area in ECC circuits, the inter-group thrombogenicity
diﬀerence can be further evaluated. As shown in Figure 4.8, blood essentially resided
on a surface area 3.10 x larger in the NOgen group than in the control group (18.02
± 4.78 m2). For surfaces with stark diﬀerences in thrombogenecity, this evaluational
parameter further characterizes blood coagulation in flow conditions as shown in this
study. It is however not helpful when evaluating the non-thrombogenecity of ECC
circuits with equal flow rates and survivals.
Although copper is an essential trace element present in normal diet, excess of
it in serum can be toxic and can have detrimental health eﬀects. Since the entire
surface of the NOgen group is coated with 10 wt% Cu nanoparticles to mediate NO
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generation from circulating RNSOs, it was therefore important to monitor the amount
of copper that may leach into blood. At the blood/polymer interface, it is free copper
ions at the polymer surface that undergo oxidation/reduction reaction to catalyze
NO generation and therefore leaching of copper. According to the food and drug
administration (FDA), about 2mg copper per day is required by the average adult
with an acceptable daily intake of 0.5mg per kg body weight. This implies that in
a 75kg man with say 5L total blood volume, the acceptable daily total Cu intake is
37mg. This will yield a blood copper concentration of 750 µg/dl. The amount of
leached copper at 4 hours was 333 ± 3.9 µg/dl. This plasma copper level is still 2.25
times lower than the acceptable daily intake.
The purpose of heparin administration in the form of a bolus and infusion was
to target ACTs between 350 - 400 seconds. This level of ACT is comparable to the
ACT regiment ( > 400 seconds) during cardiopulmonary bypass but greater than
normal range of ACTs (180 - 200 seconds) during ECMO. Earlier in the protocol
development of this study it was observed that not using systemic anticoagulation
to increase ACTs above 300 seconds in addition to local NO generation from NOgen
ECC circuits, all test ECC circuit groups clotted oﬀ. This was, perhaps, due to the
fact that the NOgen ECC circuits had a rougher surface from the presence of copper
particles. We currently do not know if that observation was entirely because of surface
roughness eﬀects or because the fiber bundle housing and core was not coated with the
NO generation material. This must be further investigated by top-coating the NOgen
fibers and NOgen tubings with a thin layer of hydrophilic polymer to smoothen the
fibers’ surface. This top coat must be thin enough to allow hydration, corrosion, and
ionization of copper at the blood/polymer interface. Coatable housings and bundle
cores must also be used for further studies so that NO is generated from tip-to-tip of
the test circuit.
Finally the inclusion of copper particles in the gas exchange fibers changes the
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original material properties of silicone. The most pertinent material property for
oxygenators is the gas transfer. Although the ECC devices were not used for oxy-
genation in this study, their gas transfer were evaluated by flowing nitrogen gas on
blood side and nitric oxide in nitrogen sweep gas on the gas side. NO transferred
across the membrane to the blood side was swept into a nitric oxide analyzer where
the NO concentration was measured. NOgen lung gas transfer was reduced by 32%
compared to silicone control lungs. This reduction in gas transfer due to a change
in material property may not significantly aﬀect gas transfer due to secondary flow
design of hollow silicone fiber oxygenators. However further testing using blood is
necessary to determine the gas transfer performance of NOgen lungs.
4.5 Conclusion
This study evaluated the first Cu-mediated NO generating hollow silicone fiber
lung in an extracorporeal circulation setup. The results indicate that NO-generating
hollow fiber lung significantly reduces blood coagulation compared to their nonNO-
generating controls. Blood flow in controls was significantly lower and their resistance
was higher than the NOgen ECC circuit group due to massive and occlusive blood
clots in contol circuits. Futhermore the amount of copper leached into plasma over the
course of the experiment was 2.25 x less than the acceptable daily intake of copper.
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CHAPTER V
NON-THROMBOGENIC
CHARACTERIZATION OF EXTRUDED
NITRIC OXIDE RELEASING SILICONE
CATHETERS
5.1 Abstract
Intravascular catheters used in clinical practice can activate platelets, leading
to thrombus formation and stagnation of blood flow. Nitric oxide (NO) releasing
polymers have been shown previously to reduce clot formation on a number of blood
contacting devices. In this work, trilaminar NO-releasing silicone catheters were
fabricated and tested for their thrombogenecity. All catheters had specifications of L
= 6 cm, inner diameter = 21-gauge (0.0723 cm), outer diameter = 12-gauge (0.2052
cm), and NO-releasing layer thickness = 200 ± 11 m. Control and NO-releasing
catheters were characterized in vitro for their NO flux and NO release duration by
gas phase chemiluminescence measurements. The catheters were then implanted in
the right and left internal jugular veins of (N=6, avg. weight = 3kg) adult male
rabbits for 4h thrombogenicity testing. Platelet counts and function, methemoglobin
(metHb), hemoglobin (Hb), white cell counts and functional time (defined as patency
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time of catheter) were monitored as measured outcomes. NO-releasing catheters
(N=6) maintained an average flux above (2 0.5) x 10 −10 mol min−1 cm−2 for over
24 h whereas controls showed no NO release. MetHb, Hb, white cell and platelet
counts and platelet function at 4h were not significantly diﬀerent from baseline (α =
0.05). However clots on controls were visibly larger and prevented blood draws at a
significantly (p<0.05) earlier time (2.3 ± 0.7 h) into the experiment whereas all NO-
releasing catheters survived the entire 4h test period. Results indicate that catheter
NO flux levels attenuated thrombus formation in a short-term animal model.
5.2 Introduction
There are 500,000 admissions to neonatal intensive care units in the U.S. each
year. Most of these babies require management through central venous, umbilical
venous or umbilical artery catheter access for the administration of either one or a
combination of the following: total parenteral nutrition, chemotherapy, fluid, blood
products, and life-saving medications [1]. These catheters are commonly made up of
poly(vinyl chloride) (PVC), polyurethane, or silicone rubber. Despite best practices,
these catheters are often compromised because of infection, thrombosis, complications
leading to an increase in morbidity, extended hospital stay, and mortality, in some
cases [2 - 5]. The risk of complication associated with catheterization is even higher
in population of predominantly premature neonates [6] whose haemostatic system is
not yet matured [7 - 8]. The overall rate of catheter occlusion is estimated to be 2.0
per 1,000 catheter days [9]
Current attempts in clinical practice to prevent clot formation involve heparin
flushing through indwelling catheters. Although its use can be appreciated, heparin
is a systemic-acting anticoagulation agent associated with bleeding in patients [10].
Its eﬀect can be especially problematic in infants because of the potential risk of
inadvertent overdose. Occluded catheters that cant be cleared with heparin are locked
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with thrombolytics like urokinase to break down clots. The catheters are locked for
hours [11] before flushing, and thereby interrupt vascular access for as long as it takes
to flush out clots from indwelling catheters if they are simply not removed. Despite
the relatively high potency of thrombolytics, there are still cases where catheters
remain partially occluded after 2h of thrombolytic locking [11].
Our attempt to improving antithrombotic properties of catheters is through sur-
face release of nitric oxide (NO). NO is a free radical gas produced by the endothe-
lium to maintain hemostasis [12 - 15]. Because the gas is both lipophilic and small it
freely diﬀuses into the platelet across its bilipid membranes to initiate several inhibi-
tions of enzymatic reactions necessary for platelet activation[16 -20]. It activates the
NO/cGMP pathway that, in turn, phosphorylates G protein-coupled surface recep-
tors, changing their conformation to decrease binding aﬃnities of agonists. Commonly
known G protein-coupled receptors on platelets include thrombin, thromboxane A2,
and adenosine diphosphate receptors. The gas also reduces secondary activation of
circulating platelets by inhibiting the release of platelets of intracellular granules.
This is achieved by blocking the release of calcium stores needed for actin-myosin
interaction required for platelets to change shape and release their granules. Unlike
other platelet inhibitors, NO has a very short halflife (milliseconds), as it is quickly
taken up by RBCs, platelets, and other NO scavengers. Thus, the anticoagulant eﬀect
occurs near the NO releasing/generating surface and elicits no eﬀect on coagulation
downstream.
The property of NO release has been imparted to catheters through surface coat-
ings. This can be problematic in terms of the duration of NO release especially in
pediatric catheters with small diameters. In this case only a thin layer of the NO
releasing material can be coated onto pediatric commercial catheters, and therefore
NO release will last for short durations. In this work, the NO releasing material was
incorporated into the wall of small diameter silicone rubber catheters for prolonged
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release. Specifically, the catheters were extruded with chemistry incorporated within
that enables post-extrusion charging with NO to create NO releasing dizeniumdiolate
structures within the walls of the extrude catheter. The controlled NO release from
the catheters was measured in vitro by chemiluminescence and finally a 4h biocom-
patibility testing of NO-secreting catheters and controls was conducted using a rabbit
model of thrombogenecity without systemic anticoagulation.
5.3 Materials and Methods
N-(6-aminohexyl) aminopropyl trimethoxysiloxane (N-(6-aminohexyl) aminopropyl-
trimethoxysiloxane (DACA-6)), potassium tetrakis(4-chlorophenyl) borate, phosphate
buﬀer saline, and tetrahydrofuran (THF) were purchased from Sigma Aldrich (St
Louis, MO). The two part silicone resin was purchased from nuSil Silicone Tech
(Carpinteria, CA). The fumed silica particles were purchased from Sigma Aldrich (St
Louis, MO) and the stainless steel mandrel was a product of Small Parts Inc. (Mari-
mar, FL). The 21-gauge angiocaths that were bonded to the extruded catheters were
purchased from Infusion Therapy Systems Inc. (Sandy, Utah).
5.3.1 Structure and Composition of NO-releasing Catheters
All extruded catheters had a trilayer structure; a base-layer, an active-layer, and
a top-layer. The active layer, where NO molecules are immobilized, is sandwiched
between the base and top layers as shown in Figure 5.1. The compositions of the
base, active and top layers are shown in Table 5.1. The base layer consisted of
silicone resin oligomers A and B in a 1:1 ratio and 5 wt% fumed silica to add stiﬀness
to the catheters. The active layer contained 1:1 silicone resin A to B, 15 wt% DACA-6
and 11 wt% by mole of DACA-6 of potassium tetrakis(4-chlorophenyl) borate. Only
silicone (1:1 resin A to B) was used as the top-coating material.
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Figure 5.1: Cross sectional composition of nitric-oxide-releasing catheters
Table 5.1: Chemical composition of base, active and top layers of nitric oxide releasing
catheter
Catheter
Layer
Resin A Resin B Fumed Silica DACA-6 Borate
Base Layer 1 part 1 part 5 wt% - -
Active
Layer
1 part 1 part - 15 wt% 11 wt%
by mole of
DACA-6
Top Layer 1 part 1 part - - -
The base, active and top layers were sequentially extruded during fabrication of
the catheters. The catheter fabrication process is shown in Figure 5.2. Stainless steel
mandrels (21 gauge) were used as cores over which catheter material was extruded
using a setup with a fixed aperture size through which mandrels are passed. After
extrusion and curing, the stainless steel cores were removed leaving behind the exper-
imental catheters. For extrusion of the base layer, 10 cm long stainless steel mandrels
were hand-fed through the catheter fabrication setup. After three passes, a uniform
coat over the mandrels was achieved. The mandrels are then stationed vertically and
cured at 500 F for 30 min. The cured base layers were then slid oﬀ the mandrels
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Figure 5.2: Setup for Extruding Nitric Oxide Releasing Silicone Catheters.
after immersion in water for 2 h. The newly formed catheter base layers were left
to dry in a drying hood for 30 min before the active layer was extruded over the
base-layer. The thickness of the active layer was achieved after 2 passes through the
extruder. The 2 layers were dried in ambient temperature for 24 h. Finally, to remove
any surface irregularities, the top layer was added with a single pass. The extruded
catheters were then dried in a fume hood for 48 h before charging the NOreleasing
group with nitric oxide.
5.3.2 Nitric Oxide Charging of Catheters and NO-release Testing
The method used to charge the active layers with NO has been previously de-
scribed [21]. In brief, the NO-releasing catheter group were charged with NO using
a NO reactor (80 psi of NO(g)) whereas the control group, having the same structure
and composition as the NO-releasing group, were not charged with NO. Catheters
were kept in the reactor for 72 h to allow the NO molecules to react with DACA-6.
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The catheters were then immediately tested for their NO release by chemilumines-
cence. NO release testing by chemiluminesence has also been described in [22]. In
brief, 1 cm long sections of the NO-reacted catheters were bathed in a chelex-treated
PBS, pH 7.34, at 37◦C. NO released was then measured with a Sievers Nitric Oxide
Analyzer 280i (GE instruments Boulder, CO). The NO release signal was integrated
over a given time, and knowing the surface area of the catheter, the flux of NO from
the surface can be readily calculated as NO concentration per unit time divided by
the total surface area of the catheters. Since all catheters were implanted 24h after
charging, their NO release after 24h of dry storage in -20◦C environment was also
tested. To test whether DACA-6 is essential for immobilizing NO molecules dur-
ing charging, catheters without DACA-6 (N=3) were charged and tested for their
NO release. In addition, to test whether borate was needed to stabilize NO release,
catheters prepared with active layers of 5% and 15% DACA-6 without borate (N=3
each) were also charged and tested for NO release.
5.3.3 Preparing Catheters for Non-thrombogencity Evaluation
All catheters, controls and NO-releasing, were cut to 6 cm long sections and
connected to a 21-gauge angiocatheter. Part of the commercial catheter was dipped
in THF and inserted into one end of the extruded catheter to bond the interface. This
assembly process was necessary for controlled and leak-free blood draws and infusions
using luer-lock syringes. The catheters were then stored in a -20◦C fridge to reduce
spontaneous NO loses.
5.3.4 Rabbit Thrombogenicity Model for Testing of Catheters
The animal handling and surgical procedures were approved by the University
Committee on the Use and Care of Animals in accordance with university and federal
regulations. A total of 6 New Zealand white rabbits (Myrtle’s Rabbitry, Thomp-
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sons Station, TN) were used in this study. All rabbits (2.5-3.5 kg) were initially
anesthetized with intramuscular injections of 5 mg/kg xylazine injectable (AnaSed
Lloyd Laboratories Shenandoah, Iowa) and 30 mg/kg ketamine hydrochloride (Hos-
pira, Inc. Lake Forest, IL). Maintenance anesthesia was administered via a diluted
intravenous (IV) infusion of ketamine at a rate of 15 mg/kg/h. In order to maintain
blood pressure stability, intravenous (IV) Lactated Ringers solution was given at a
rate of 10 ml/kg/h. The paralytic, pancuronium bromide (0.2 mg/kg, IV), was ad-
ministered to have the animal totally dependent upon mechanical ventilation which
was done via a tracheotomy and using a Sechrist Infant Ventilator Model IV-100
(Sechrist, Anaheim, CA). For monitoring blood pressure and collecting blood sam-
ples, the rabbit right carotid artery was cannulated using a 16-gauge IV angiocatheter
(Jelco, Johnson & Johnson, Cincinnati, OH). Blood pressure and derived heart rate
were monitored with a Series 7000 Monitor (Marquette Electronics Milwaukee, WI).
Prior to placement of the catheters, the rabbits left and right internal jugular veins
were isolated and baseline hemodynamics were recorded. Arterial blood pH, pCO2,
pO2, total hemoglobin and methemoglobin were determined using an ABL 725 blood
gas analyzer and OSM3 Hemoximeter (Radiometer Copenhagen Copenhagen, DK).
In addition, baseline blood samples were collected for platelet and total white blood
cell (WBC) counts utilizing a Coulter Counter Z1 (Coulter Elec- tronics Hialeah,
FL), ACT was determined using a Hemochron Blood Coagulation System Model 801
(International Technidyne Corp. Edison, NJ), and platelet function was determined
using a Chrono-Log optical aggregometer model 490 (Havertown, PA). Animals had
no systemic anticoagulation throughout the experiment.
After baseline blood measurements, catheters were placed 1 cm distal to the bifur-
cation of the right and left jugular vein. A control and an NO releasing catheter were
placed in each animal, and the placement was varied so that 3 animals had controls
on the right internal jugular vein and 3 animals had controls in the left internal jugu-
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lar vein. The catheters were locked with 0.9% saline (Hospira Inc, Lake Forest, IL).
At 20 min intervals, each catheter was tested for its ability to allow blood draw and
saline infusion using a 1cc luer-lock syringe. Each animal received a 400 U/kg sodium
heparin dose prior to euthanasia to prevent necrotic thrombosis. The animals were
euthanized using a dose of Fatal Plus (130 mg/kg sodium pentobarbital) (Vortech
Pharmaceuticals Dearborn, MI). The internal jugular veins were dissected out from
the site of catheter entry to approximately 1 cm below the end of the catheter. The
jugular vein was cut parallel to the length of the catheter, and the catheter was re-
moved. The catheters were photographed and a 1 cm section of the tip of the catheter
was preserved in glutaraldehyde for obtaining a scanning electron micrograph (SEM).
5.3.5 Blood sampling
Rabbit whole blood samples were collected in non-anticoagulated 1 cc syringes for
ACT, 10% anticoagulant containing sodium citrate, sodium phosphate and dextrose
(ACD) (Hospira, Inc. Lake Forest, IL) by volume of blood collected in 3 cc syringes
for cell counts, aggregometry and FACS analysis and 1 cc syringes containing 40
U/ml of sodium heparin (APP Pharmaceuticals, LLC Schaumburg, IL) for blood gas
analysis. Every hour up to 4 h, following placement of the catheters, blood samples
were collected for in vitro measurements. Samples were used within 2 h of collection
to avoid any artifactual activation of platelets and monocytes. Also all data collected
after baseline was corrected for the hemodilution eﬀect of IV fluids.
5.3.6 Platelet Aggregometry
A previously published method [21] for platelet aggregometry was used to assess
platelet function. In brief, rabbit platelet aggregation was assayed based on Borns
turbidimetric method using a Chrono-Log optical aggregometer. Citrated blood (1:10
blood to ACD) was collected (6 mL) and platelet-rich plasma Platelet-Rich Plasma
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(PRP) was obtained by centrifugation at 110 g for 15 min. Platelet-poor plasma
Platelet-Poor Plasma (PPP) was obtained by another centrifugation of the PRP-
removed blood sample at 2730 g for 15 min and was used as the blank for aggregation.
PRP was incubated for 10 min at 37◦C and then 40 mg/mL collagen (Chrono-PAR
No 385 Havertown, PA) was added. The percentage of aggregation was determined
3 min after the addition of collagen using Chrono-Log Aggrolink software.
5.3.7 Statistical Analysis
One-way ANOVA with repeated comparison of the means using Tukeys post hoc
tests were done to compare the dependent variables between the NO-releasing and
control catheter groups. A p-value < 0.05 is regarded as significant.
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5.4 Results
5.4.1 Extruded Catheter
The finished catheter shown in Figure 5.3A was partly filled with a mixture of
water and blue food dye for perspective visualization. The extruded NO releasing
portion of the catheter, left of the demarcation, was connected to a 21 ga angiocath.
All implanted catheters had the following dimensions: L= 6 cm, ID = 21-guage (0.723
mm), and OD = 12-gauge (2.052 mm). A cross secitonal representative is shown in
Figure 5.3B. The lumen is to the top left corner followed by the base, active, and top
layers. Since the NO flux of the catheters is dependent on the amount of DACA-6
and subsequent in-situ diazeniumdiolation of the secondary amine site of this species,
the thickness of the active layers was measured. The opaque active layer thickness
averaged 200 ± 11 µm (N= 6 catheters).
Figure 5.3: Extruded silicone-rubber nitric-oxide-releasing catheter, a) and cross sec-
tion of catheter, b).
5.4.2 NO Release from DACA-6 Doped Silicone Catheters
NO release from control and NO-charged catheter groups is shown in Figure 5.4.
As expected control catheters did not release NO whereas NO-charged catheter se-
creted NO for the test duration. On average (N = 6) NO releasing catheters released
NO at a flux of ca. 6 ± 0.92 x 10−10 mol min−1 cm−2 steadily for first 4 h of testing.
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After 24 h of dry storage in a -20 ◦C freezer, the flux levels dropped to ca. 2 ± 0.5
x 10−10 mol min−1 cm−2 on average (N=6). In brief, the NO flux from catheters in-
creased for the first two hours until the release rate peaked. Thereafter, the NO stores
within the walls of the catheters started to be depleted gradually for the remainder
of the in vitro test period.
The outcomes of the eﬀects of DACA-6 and borate on NO release are shown in
Figures 5.6 and 5.5. Catheters without borate did release larger bursts of NO within
an hour but thereafter released relatively lower flux levels of NO. The addition of
borate helped reduce this burst for a more sustained NO release profile (Figure 5.4).
The catheters prepared without DACA-6 did not release significant levels of NO after
charging. Low levels of NO release were measured from these catheter types, likely
because of NO gas has high solubility in silicone rubber materials. However, this
temporary storage of NO dissipates very quickly during NO release testing. NO flux
density (NO), (x 10 -8 mol/cm2), of catheters was function of wt% DACA-6 according
to the relationship NO = 0.38(wt% DACA-6) + 0.21, R2 = 0.99 (See Figure 6). Higher
NO flux levels were sustained for over 24h at 40wt% borate inclusion compared to no
borate.
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Figure 5.4: Nitric oxide release from control catheters (15%DACA-6, 40%borate by
mole of DACA-6, uncharged) and NO releasing catheters (15%DACA-6,
40%borate by mole of DACA-6, NO charged) as measured by chemilu-
minescence. Control catheter samples were bathed in a chelex-treated
phosphate buﬀer saline (pH 7.34, 37◦C) medium and NO release was
measured with a Nitric oxide analyzer
Figure 5.5: Nitric oxide release from catheters(0%DACA-6 and 0%borate, 5%DACA-
6 and 0%borate, 15%DACA-6 and 0%borate) as measured by chemilu-
minescence. Catheter samples were bathed in a chelex-treated phosphate
buﬀer saline (pH 7.34, 37◦C) medium. NO released was measured with a
Nitric oxide analyzer
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Figure 5.6: NO flux density of NO-releasing catheters as a function of their wt% of
DACA-6 amounts
5.4.3 Thrombogenicity Testing Outcomes
All NO-releasing silicone catheters lasted the entire duration of the thrombo-
genecity testing. There were no blood-drawing or saline-infusion incidents with any
of the NO-releasing catheters. However 4 out of 6 control catheters became occluded
before the end of the in vivo testing experiments. Catheter occlusion was interpreted
as the first time when blood draw was totally impeded. Further investigations for
clots on the occluded catheters using SEMs and photography were also performed
after carefully dissecting out the implanted catheters. Representative images of clots
on implanted control catheters and explanted control and NO-releasing catheters are
shown in Figures 5.7 and 5.8.
Biological markers such as metHb, Hb, WBC count, platelet count and platelet
function, frequently used to measure NO toxicity, inflammation, and blood activation,
were collectively used for a general evaluation of the biocompatibility of the catheters.
MetHb (p = 0.1), WBC count (p = 0.8), platelet counts (p = 0.2) and platelet function
(p = 0.9) at 4h were not significantly diﬀerent from baseline (α = 0.05). Basically
the surface area (3.9 ± 0.4 cm2) of the catheters are so small that 4 h of blood
exposure is not long enough to eﬀect significant changes in those biological markers.
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Figure 5.7: Clots on control catheters after 4hr - implantation in the jugular vein of
adult New Zealand male rabbits
Figure 5.8: Clots on control and NO-releasing catheters. All NO-releasing catheters
showed no occlusive clots at their tips after explantation (top) whereas
control catheters (bottom) got completely occluded by clots before the
end of the 4hr-experiments.
Hemoglobin, however, did decrease by a significant amount (14%, p < 0.05) after 4
h due to hemodilution.
An important evaluation parameter of any catheter is its ability to remain patent.
In our study, the average time until the first blood draw incident occurred was termed
the patency time. All NO-releasing catheters remained functional after 4 ± 0 h
whereas the controls’ functional time averaged 2.3 ± 0.7 h (Figure 5.9). There was a
100% survival in the NO-releasing group and 33.33% in the control group.
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Figure 5.9: In vivo functional time of control and NO-releasing catheter groups. Func-
tional time was interpreted as average time until first blood draw incident
per catheter group
5.5 Discussion
Research is needed to develop small (21 to 24 gauge) intravascular catheters that
function similar to vascular endothelium, producing nitric oxide locally, preventing
development of biofilm, repelling platelets and preventing thrombus formation. The
risks of clotting and infection with current catheters occur in all patients (including
children and adults), but the problem is most serious in newborns because the vessels
are so narrow that even a small thrombus can occlude the catheter, and because the
newborns host response to bacterial infection is not fully developed.
Preventing these risks would have a major impact on neonatal care, and even
greater impact on all patients who require intravascular catheters. It would decrease
morbidity and mortality, and decrease costs by shortening hospital stay while increas-
ing survival. Creating catheters from materials that are highly resistant to thrombus
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and biofilm formation would solve these major problems. Current approaches do not
eliminate these problems. Catheters with heparin bonded to the surfaces are available
[23 25], but systemic heparin injections/infusions are still required. Catheters coated
with antiseptics or antibiotics are available [26], and do decrease the risk of infection
somewhat, but do not prevent biofilm formation on the outer surface of the catheter
in contact with blood/tissue. Catheter-related sepsis (or the possibility of catheter
sepsis requiring catheter removal) is still a major problem in the hospital setting [26].
The results of this study suggest that NO-releasing catheters attenuate thrombus
formation in a short-term animal model, and that such catheters can be fabricated by
extrusion with the precursors for NO release chemistry incorporated in to the walls
of the catheters.
Key properties of the extruded catheters are the level of NO flux they secrete and
the duration of the NO secretion. The levels of NO release from catheters (6 x10 −10
mol min−1 cm−2) after NO charging and (ca 2 x 10−10 mol min−1 cm−2) after 24h of
dry storage were comparable to endothelial level of NO flux. Although the catheters
were stored dry and at a low temperature (-20◦C) to reduce spontaneous release of
NO, there was a 66.7% decrease in flux levels when tested after 24 h. Therefore such
storage condition may not be ideal for long- term storage as most of the stored NO
may be lost. In this study, however, the levels of NO release after 24 h storage proved
adequate for maintaining catheter patency.
If further improvements in the NO release profile are necessary, they might be
achieve by adjusting the thickness of the active layer, the availability of anionic bo-
rate sites in the active layer, and the NO charging conditions. The eﬀect of catheter
wall thickness is already explained above. The inclusion of anionic sites in the ac-
tive layer sustains NO release by keeping the microenvironment of the catheters in
a more acidic condition [27]. Anionic agents such as borate (used in this study),
dibutyltin dilaurate (DBTDL), and the United States Food and Drug Administra-
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tion approved poly(lactic-co-glycolic acid) (PLGA) are currently being investigated in
detail to determine what levels allow sustained NO release from hydrophobic polymers
doped with diazeniumdiolates for a 30 d period. Their stability may also be impor-
tant in keeping the acidic conditions necessary for sustained release. For instance
slow-degradation-rate PLGAs may serve as a better regulator of NO release than a
faster-degradation-rate PLGA. Lastly, the optimal charging time of these catheters
are, at this point, unknown and needs to be examined in detail. The method of
loading NO into catheters was based on previous work on silicone membranes [21]. A
combination of longer NO charging and high NO-payload amines with stable anionic
sites may improve the longevity of NO release from catheters.
The short-term rabbit model used to test the biocompatibility of catheters is
a well-developed model that allowed for monitoring an array of biological markers.
There are however some improvements that can be made. For example, the 20-min
blood withdrawal test interval may mask true diﬀerences between control and test
catheters, as forming clots maybe broken up before they grow into larger occlusive
masses. Blood draws could be done every hour, instead, such that clots have a greater
duration to form. This methodology would be more aggressive in teasing out diﬀer-
ences in performance between catheter test groups but would require an animal model
with catheter placement lasting for a longer period of time (e.g., 8-24 h). Therefore,
the next step in testing these extruded NO-releasing catheters should focus on longer-
term outcomes using appropriate animal models. The longer term model would also
allow for examination of the antimicrobial eﬀects of the NO-releasing catheters. This
measure will be added during the longer-term thrombogenicity testing.
5.6 Conclusion
The goals of this study were to investigate the following: fabrication of silicone
catheters, NO charging of catheters to release endothelial levels of NO in a con-
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trolled environment, characterization and investigation of how to control NO flux
and non-thrombogenic evaluation of the NO-releasing catheters in vivo. The catheter
fabrication process was adequate for the manufacturing of silicone catheters for non-
thrombogenic evaluation. Quality controls built into the fabrication process ensured
the manufacturing of 12 gauge OD catheters that could be implanted into the right
and left internal jugular veins in adult rabbits. Since the catheters walls were fab-
ricated in layers, chemistry could be incorporated into their active layers to allow
loading of NO into their walls. NOcharged catheters also released endothelial levels
(> 2 x 10 −10 mol min−1 cm−2) of NO upon stimulation in a PBS solution (37◦C,
pH = 7.34). Their NO flux, as measured by chemiluminescence, showed that 1) NO
flux depended of DACA-6 concentration and 2) high levels of sustained NO release
depended on borate inclusion. NO flux density (NO), (x 10−8 mol cm−2), of catheters
was function of wt% DACA-6 according to the relationship NO = 0.38(wt% DACA-6)
+ 0.21, R2 = 0.99. In addition higher NO flux levels were sustained for over 24h at
40wt% borate inclusion compared to no borate. Overall, 100% of the NO-releasing
catheters survived the 4h test duration compared to a 33% survival of the non-NO
releasing controls. For NO-releasing catheters to find use in both pediatric and adult
care, fabrication of NO-releasing catheters with ODs as small as 21 gauge should
be investigated. The duration of NO release should also be studied in order to ex-
tend their patency up to 30 d and beyond. To get there, diﬀerent NO immobilizing
compounds and anionic sites must be investigated.
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CHAPTER VI
NITRIC OXIDE IN SWEEP-GAS FOR LOCAL
CLOT INHIBITION IN OXYGENATORS
6.1 Abstract
Studies have explored supplementation of nitric oxide Nitric Oxide (NO) in sweep
gas to reduce platelet adhesion, activation, and coagulation within oxygenators with
mixed results. The mixed results may be due to wide variations from study to study
in NO concentrations, oxygenator types, blood flow rates, and in vitro and in vivo
models. Each of these factors is likely to aﬀect NO flux rates from the gas exchange
membrane. However, these flux rates have never been measured or modeled, making
interpretation of the results diﬃcult. In this study, in vitro experiments were con-
ducted to determine the flux rates through clinical oxygenators at a range of sweep
gas NO concentrations.
Specifically, the Biolung and the Terumo Capiox RX25 (N = 3 each) were per-
fused with a liter of water circulating at 4 L/min while NO gas at 10, 100 and 1000
ppm concentrations in nitrogen were swept through the devices at 8 L/min. NO
concentration in the water was measured at baseline prior to initiating NO flow and
at 1,3 5, 10, 15, and 30 minutes after initiation. The NO concentration data were
then used to calculate NO flux by dividing the change in the amount of dissolved
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NO per unit time by the total surface area of the artificial lung. The flux data was
used to calculate the mass transfer coeﬃcient, kc, by dividing the flux by the diﬀer-
ence between the maximum NO concentration (NO concentration at its solubility at
standard temperature and pressure) and NO concentration at time t. The flux rates
of NO for each lung was then calculated as the product of their average kc’s and the
maximum NO concentration.
The kcs of the Biolung and the Capiox RX25 were 0.05 ± 0.001 cm/min and 0.025
± 0.004 cm/min respectively. From these values, the calculated NO flux from the
Biolung and the Capiox RX25 at 5000 ppm NO/N2 sweep gas were 4.85 ± 0.1 and
2.43 ± 0.007 (x 10−10 mol/cm2/min) respectively. These results indicate that the
range of sweep gas NO concentrations previously tested were insuﬃcient to generate
flux rates that significantly limit platelet deposition, but that further increases are not
warranted due to the high levels of mHb that are generated. Future studies should
focus on passivating surfaces to platelet deposition such that lower NO flux rates may
be suﬃcient to counteract platelet activation.
6.2 Introduction
In the previous chapters, surface functionalization with NO via chemical proce-
dures have been evaluated in flat silicone membranes, hollow silicone fibers, artificial
lung ECC circuits, and intravascular catheters. The chemical procedure employed
for these applications modifies surfaces to either release of generate NO. In artifi-
cial lungs where the longevity of NO production is pertinent, NO generation shows
more practicality than NO release. In the NO generation method however, Cu tox-
icity due to leaching of Cu particles from the surface of a biomaterial into blood is
a real problem. This problem can be completely avoided by a relatively easier ap-
proach of functionalizing the gas exchange surfaces of artificial lungs with NO. In this
approach, NO gas is supplementated into the sweep gas of artificial lungs, and the
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NO gas continuously diﬀuses across the gas exchange fibers to provide a flux at the
blood/polymer interface. Not only does this method avoid the problem of toxicity
from metallic catalysts but also preserve the longevity of NO production aﬀorded by
the NO generation procedure.
NO gas has a long history for its capacity to inhibit platelet adhesion to gas
exchange membranes of oxygenators [1]. Its utility in controlling clots via NO in-
halation by patients during CPB surgery, through supplementation into sweep gas
during extracorporeal membrane oxygenation of severe pulmonary hypertension pa-
tients, or for reducing biomaterial-induced clot formation in vitro experimentation
has shown outcomes with little consensus. A wide range of sweep gas NO concentra-
tions (15-1000 ppm) has been tested using diﬀerent oxygenator types and membranes
in CPB and extracorporeal membrane oxygenation ECMO since 1995. This range is
reflective of the fact that there is no agreement on what NO concentration is optimal
for: maintaining oxygen carrying capacity of red blood cell Red Blood Cell (RBC)s
(by keeping methemoglobin Methemoglobin (MetHb) below 5%), inhibiting platelet
activation, maintaining platelet function, maintaining good hemodynamics and hemo-
compatibility while remaining non-toxic to cells.
One of the earliest NO sweep gas work was conducted using 15, 40, and 75 ppm
sweep gas NO concentration to study their eﬀect of blood coagulation in vitro. Sweep
gases (NO in nitrogen bled into 5%CO2 in air) were flowed into oxygenators primed
with heparin-treated blood recirculating at 0.6 L/min in an ECC for 24 hours [2].
Plasma nitrate, cyclic guanosine monophosphate levels, and platelet count were sig-
nificantly higher in the NO circuits than in the control circuits (p<0.01). Beta throm-
boglobulin released from an activated platelet’s alpha granules was observed at lower
levels in the NO circuits (p<0.01). No diﬀerence was observed in platelet’s serotonin
content and membrane glycoprotein Ib density between circuits. There were no dose-
response eﬀects in all measured variables for the NO concentrations tested. Similar
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positive results using low sweep gas NO concentration (20ppm) were also reported
by Keh et al 1999 [3]. In their study, the NO gas was supplied into M18 Jostra
oxygenators in a simulated ECMO circuit primed with 1IU/ml heparinized blood.
Platelet count, betathromboglobulin, and methemoglobin concentrations were moni-
tored in the circulating blood (0.6 L/min) for 4h. Platelet count and methemoglobin
concentrations were significantly higher (p<0.01) in NO group than in controls. Be-
tathromboglobulin was also significantly lower in the NO group (p<0.05). Due the
positive eﬀect of 40 ppm sweep gas NO seen in vitro by Mellgren et al 1996 [2],
the same group investigated the eﬀect of that concentration during CPB of twenty
patients[4]. Unfortunately there was no significant diﬀerences in platelet count and
function between control and NO groups. Platelet function, as measured by glyco-
protein GP I/Ib and GP IIb/IIIa exposure, was preserved in both groups.
Based on previous outcomes of positive in vitro conclusions at a low sweep gas
NO concentrations and disappointing in vivo conlcusions, several sweep gases with
higher NO concentrations have thus been tested. In a study by Tevaearai et al 2000
[5], a slightly higher NO concentration (80ppm, in O2 and N2) was infused into oxy-
genators in ECC during a CPB procedure in calfs to determine the eﬀect of NO on
local clot formation. The surface area of the oxygenator covered with clots was sig-
nificantly reduced from 5.78 ± 3.80% in the control group to 0.54 ± 0.41%, (p<0.05),
in the NO group. Interestingly platelet count dropped to 60% of basal value and
its evolution during the 6-hour experiment was comparable in both groups [5]. In a
diﬀerent study, a 100ppm NO/N2 was utilized for inhibiting platelet activation inside
membrane oxygenators supporting 47 CBP patients. Methemoglobin remained below
4% and there was no significant diﬀerence in platelet count between NO and control
groups (p< 0.05). Furthermore, NO had no detectable eﬀect on the levels of beta
thromboglobulin and did not aﬀect bleeding. Methemoglobin levels also remained
in the safe range (up to 4%) during the entire 3-hour procedures [6]. Due to yet
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undesirable outcomes, other research groups ventured for higher concentrations. Two
sweep gas NO concentrations (100 and 200ppm NO/N2) were infused into hollow
fiber oxygenators to test for their ability to inhibit platelet activation. Platelet count
decreased with 100ppm NO concentration during the first hour and platelet factor 4
(PF4) increased also in this time frame. At 200 ppm sweep gas NO concentration,
there was significant reduction in platelet adhesion in the NO group, and no diﬀerence
was observed in PF4 levels between the NO and non-NO groups after 1 h. Plasma
PF4 however, increased after an hour regardless of sweep gas NO concentration [1].
Even yet higher sweep gas NO concentrations have been tested. In work conducted
by Sly et al 1996 [8], adult pigs undergoing CBP were supported on a membrane oxy-
genator infused with a 500ppm NO/N2 sweep gas at 1 L/min. Platelet adherence and
aggregation decreased compared to their controls (p<0.05), and no diﬀerence in flow,
mean arterial pressure, and hematocrit was observed between control and NO groups.
These conclusions held when sweep gas NO concentration was increased to1000 ppm.
Methemoglobin however, doubled from 4% when sweep gas NO concentration was
increased to 1000ppm [7, 8]. From these studies, it seems that the bases for selecting
a sweep gas NO concentration solely relied on previous blood coagulation outcomes
without regard for what the NO flux would be on the surfaces of gas exchange mem-
branes. In this work, NO flux rates on the Biolung and Terumo CapioxRX25 were
investigated using 10 - 1000ppm NO/N2 sweep gas NO concentrations. Flux rates at
diﬀerent concentrations are also predicted and compared to endothelial levels of NO
flux.
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6.3 Materials and Methods
6.3.1 In vitro Study
Circulation Setup: To determine NO flux rate across oxygenator fibers, water was
circulated in a circuit, as NO sweep gas flowed countercurrently through the oxygena-
tors as shown in Figure 6.1. The concentration of NO in the fluid was then measured
at diﬀerent time points. Specifically, 1000 cc of fluid was pumped (stockert multiflow
roller pump) from the reservoir into the lungs (Biolung MC3, Ann Arbor, MI and
Terumo Capiox RX 25) and returned to the reservoir through a 0.5
￿￿
Tygon tubing
at 4 L min−1. 10, 100 and 1000 ppm NO/N2(Cyrogenic gases, Detroit MI) sweep
gases were separately supplied at 8 L min−1 and monitored with an air flow meter
while a TS410 transit-time tubing flow meter (Transonic systems Inc. Ithaca, NY)
monitored fluid velocity. The concentration of NO in the bulk fluid was measured by
drawing 3 mL fluid samples from the outlet conduit of the lungs through a stopcock
at baseline (time zero), 3, 5, 10, 15, and 30 minutes for each sweep gas concentra-
tion. After each 30 minute run, the circuit was filled with fresh water for the next run.
Procedure for Measuring Nitric Oxide Concentration in Water:
The concentration of NO in the bulk fluid was measured by drawing 3 mL samples
from the outlet conduit of the lungs through a stopcock prior to the initiation of
sweep gas flow and at 3, 5, 10, 15, and 30 minutes after initiation of flow. After each
30-minute run, the circuit was filled with fresh water for the next run. Drawn samples
were immediately (<10 sec) introduced into a pre-prepared sample cell of a Sievers
nitric oxide analyzer 280 unit (GE analytical instruments, Boulder, CO) setup to mea-
sure the NO content. Prior to sample introduction the sample cell was purged with
N2 to remove oxidative species from the cell. A 3-minute baseline recording of the
dry cell was then done before drawn samples were injected. At this point, no nitrate
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Figure 6.1: Nitric oxide in sweep gas circulation setup.
or nitrite reducing agents were added to the samples. Only NO dissolved in water
during circulation was degassed out with N2 into the Nitric Oxide Analyzer (NOA)s
sample unit system for measurements. NO released from the samples was measured
for at least 5 minutes after the measurement signal returned to baseline levels. N=
3 measurements were taken at each sampling time for each lung. A total of N=9
samples were analyzed at each sampling time.
Recovery of Scavenged Nitric Oxide:
A standard nitrite reduction protocol using a purge vessel (GE analytical instruments,
Boulder, CO), acetic acid and potassium iodide (Sigma Aldrich, St Louis MO) was
used to reduce any nitrites that were formed in the water during circulation. This
procedure can be referred to in the Nitric Oxide Analyzer manual and it ensures that
all NO scavenged into nitrites and nitrates by oxidative species was recovered. Nitrite
is the predominant byproduct formed when nitrogen and oxidative species react in
water so scavenged NO was recovered only from nitrites in this experiment. In short,
three 50 µL aliquots of the degassed sample were injected in succession into the purge
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vessel containing acetic acid and potassium iodide. The average of the areas under
the NO release profile was then used to estimate total recovered NO.
Calculation of NO Concentration in Water:
In order to preserve convention, the units of concentration (parts per million/billion),
as recorded by our NOA was converted to moles/L. The number of moles of NO,
n(NO) (moles), per 3mL water samples, was the product of total NO content in
the sample, NOtotal (ppb* sec), which was calculated as the area under the NO
release curve, and NOA’s sampling inlet system flow rate, Q (ml/sec), and mL-to-
moles conversation factor for an ideal gas, C in equation (6.1e). This formulation was
expressed as:
n(NO) = NOtotal ×Q× C Nitric Oxide Concentration (6.1a)
NOtotal = NOtime(t) − NObaseline Net Nitric Oxide (ppb.sec) (6.1b)
Q = 3.33 ml/sec NOA’s Flow Rate (6.1c)
ppb = ( x 10−9) NOA’s sensitivity unit (6.1d)
C = 22400 mole/mL Ideal gas molecules per miliLiter (6.1e)
The data generated from equation (6.1a) was then used to calculate the n(NO)
per liter of water (NO concentration in mol/L). Equations (6.1b), (6.1c), and (6.1d)
represent the total NO measured, the nitric oxide analyzer’s gas inlet flow rate, and
its sensitivity unit respectively.
NO Flux Across Gas-exchange Membranes:
NO flux, JNO (mol min−1cm−2), across each oxygenator was calculated by dividing
the product of its total gas-exchange fibers surface area, SA (cm2), and duration of
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sweep gas flow, t (mins), into the change in NO concentration, [NO], as expressed in
equation (6.2a).
JNO = ∆[NO]/(∆t× SA) (6.2a)
Estimating NO Flux at Time Zero:
Solubility of NO in water at STP is reported to be 1.94 x 10−3 mol L−1 atm−1
[9]. For our flow conditions and sweep gas blend, the theoretical solubility of NO in
water should be lower, as the solubility of gases in solvents is directly proportional
to the partial pressure of the gas interfacing with the solvent. In our setup, the
partial pressure exerted by NO, p(NO) (atm), will be approximately proportional to
its gas proportion in the sweep gas, NO/N2 (ppm). Assuming the sweep gas exerts
a total pressure of 1 atm, the solubility and maximum theoretical concentration of
NO, [NO]max (mol L−1), in water can be estimated using equations (6.3a) and (6.3b)
respectively.
Solubility(NO) = 1.94 x 10−3 (mol L −1 atm −1)× NO/N2 (6.3a)
[NO]max = Solubility(NO)× p(NO) (6.3b)
where p(NO) = NO/N2 × 1atm (6.3c)
First, the [NO]max was estimated using the theoretical solubility of NO in water.
Second, the mass transfer coeﬃcient, Kc, at each time point was calculated using
equation (6).
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Kc = JNO/([NO]max - [NO]t) (6.4a)
In brief, Kc was calculated by dividing the diﬀerence between the maximum theoreti-
cal NO concentration and measured NO concentration into the NO flux. Finally, NO
flux at time zero for each lung type was estimated as the product of their average Kc
and the maximum theoretical NO concentration for each sweep gas blend.
6.4 Results
6.4.1 NO Concentration in Fluid
Typical purged NO profile as measured by the NOA is shown in Figure 6.2. The
levels of purged NO detected by chemiluminescence decreased over time as the dis-
solved NO in the test solution purged. In addition, scavenged NO was recovered from
samples that were already purged. Specifically, three 50 µL aliquots of the purged
sample were injected into the purge vessel and the areas under their peaks were then
calculated and averaged to estimate the total residual NO.
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Figure 6.2: Representative nItric oxide release profile from degassed sample fluids.
Figure 6.3: Representative nitric oxide release profile from reducing nitrites in de-
gassed samples. Three 50 µL aliquotes(peak 1, peak 2 and peak 3) of
the degassed sample were treated to reduce nitrites to nitric oxide gas
which was then degassed from samples and measured with a nitric oxide
analyzer. This NO release profile was from a sample perfused with 10
ppm NO/N2 sweep gas for 30 minutes.
For each sweep gas blend, NO concentration in the circulating fluid was determined
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using equation (6.1a). As shown in Figure 6.4, the NO concentration rapidly builds
up in the fluid within 10 minutes and plateaus thereafter when the Biolung was used
as the gas-exchanging device. For the 100ppm and 1000ppm NO/N2 sweep gas blend,
NO concentration (mol/L) dynamics was similar in both Biolung and Capoix devices.
It increased from 1.5 x 10−7 at 1 minute to 2.8 x 10−7 at 30 minutes with the100ppm
gas and from 9.16 x 10−7 to 1.80 x 10−6 with the 1000ppm gas. However in the 10ppm
NO/N2 blend, NO concentration was higher with the Capiox. With the capiox RX25,
it increased from (3.87 x 10−7) to (7.28 x 10−8) and (1.4 x 10−8) to (1.74 x 10−8) with
the Biolung.
Figure 6.4: Nitric oxide gas dissolved in circulation water after diﬀusing through the
gas exchange membranes of the Biolung and Capiox rX25.
NO flux across each oxygenator was calculated by dividing the product of total
surface area of its gas-exchanging fibers and duration of sweep gas flow by the change
in NO concentration. As expected NO flux into the fluid was higher soon after flow
began Figure 6.5, as NO concentration in the fluid at this point was low. For each
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lung and sweep gas blend tested, flux gradually decreased as the NO concentration
increased in the circulating fluid.
Figure 6.5: NO flux across membranes of the Biolung and Capiox RX25 using 10,
100, and 1000ppm NO/N2 sweep gases.
6.4.2 Estimating NO Flux from the Biolung and Capiox RX25 fibers at
Time Zero
Solubility of NO in water at standard temperature and pressure Standard Tem-
perature and Pressure (STP) is reported to be 1.94 x 10−3 mol L−1 atm−1 [9]. For
our flow conditions and sweep gas blend, the theoretical solubility of NO in the fluid
should be lower, as NO gas exerts a partial pressure proportional to its percentage in
the sweep gas. Table 6.1 shows the Solubilities of NO in diﬀerent NO/N2 concentra-
tions and their corresponding maximum NO concentrations in fluid.
Theoretical solubilities of our various sweep gas blends, the NO concentration in
the fluid, and the mass transfer coeﬃcient of the gas exchange fibers of each lung
were used to estimate the NO flux across the fibers at time zero. Time-zero NO flux
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Table 6.1: Solubilities of NO in diﬀerent NO/N2 concentrations and their correspond-
ing maximum NO concentrations in fluid
Sweep gas blend
(NO/N2, ppm)
Solubility
(mol L−1 atm−1)
Theoretical [NO]max
(mol/L-1)
10 1.94 x 10−8 1.94 x 10−8
100 1.94 x 10−7 1.94 x 10−7
250 4.85 x 10−7 4.85 x 10−7
1000 1.94 x 10−6 1.94 x 10−6
2000 3.88 x 10−6 3.88 x 10−6
2500 4.85 x 10−6 4.85 x 10−6
5000 9.70 x 10−6 9.70 x 10−6
is interpreted as flux just after sweep gas flow started.
The mass transfer coeﬃcient at each time point in Figure 6.6 was calculated by
dividing the diﬀerence between theoretical NO concentration and measured NO con-
centration by the calculated NO flux at that time point. The mass transfer coeﬃcient
of each oxygenator was then estimated by curve-fitting the dominating values (first
ten minutes) of the mass transfer coeﬃcient data for all sweep gas blends. See Fig-
ures 6.7 and 6.8. The estimated mass transfer coeﬃcient at time zero for the Biolung
and Capiox RX25 oxygenators were 0.05 cm/min and 0.025 cm/min respectively.
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Figure 6.6: Evolution of the mass transfer coeﬃcient, (kc), of the Biolung and Capiox
RX25 oxygenators at 10, 100, and 1000ppm NO/N2 sweep gases.
Figure 6.7: Time-zero estimation of the NO flux of the Biolung oxygenators N=4
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Figure 6.8: Time-zero estimation of the NO flux of the Capiox RX25 oxygenators
N=4
NO flux at time zero for each lung was then calculated by multiplying the esti-
mated mass transfer coeﬃcient of the lung by the theoretical maximum NO concen-
tration for each sweep gas blend. The predicted NO flux at time zero for various gas
blends (tested and untested) per lung is shown in Table 6.2.
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Table 6.2: Predicted peak flux of NO from fibers of primed Biolung and Capiox RX25
oxygenators in 1 L circulation setup
Predicted flux at time 0, (× 10−10 mol/min/cm2)
NO/N2 sweep gas
Concentration, (ppm)
Biolung Terumo RX25
10 0.009 ± 0.0002 0.005 ± 0.0001
100 0.097 ± 0.002 0.05 ± 0.001
1000 0.485±0.009 0.24±0.001
2000 0.970±0.02 0.48±0.001
5000 4.85±0.1 2.43±0.007
6.5 Discussion
NO fluxes generated from the tested range of NO sweep gas blends are able to
eﬀect small anticoagulatory benefits, as reported in [11] and also shown in this work.
Although these flux levels oﬀer some benefit, they are insuﬃcient to significantly limit
platelet deposition on biomaterials. Higher NO concentration is needed for platelet
inhibition. However, high NO levels produce MetHb at levels incompatible with life.
In the setting of our study, NO is fighting both the eﬀects of protein deposition and of
thrombin on blood coagulation. Our hypothesis is that if the biomaterial’s surface is
functionalized so that it inhibits protein or platelet deposition, low levels of NO may
prove more eﬀective at inhibiting blood activation. At such low levels, the problem
with mHb buildup could also be avoided. Future studies should focus on passivating
surfaces to platelet deposition such that lower NO flux rates may be suﬃcient to
inhibit platelet activation.
The solubility of NO in water at standard temperature and pressure has been
163
extensively studied and, perhaps, the most comprehensive report [10] on this subject
reported it to be 1.94 x 10−3 mol L−1 atm−1. This value was used to calculate the
NO solubility levels at partial pressure per each sweep gas blend (See Table 6.1).
These theoretical solubility levels should dictate the maximum NO concentration lev-
els in the circulating fluid per sweep gas blend. To check for this, the maximum NO
concentrations calculated from theroretical NO solubility values were compared to
maximum experimental NO concentration levels. For the 1000ppm NO sweep gas
blend, the ratio of maximum experimental NO concentration for both Biolung and
Capiox RX25 (1.80 x 10−6 mol L−1) to the maximum theoretical NO concentration,
1.94 x10−6 mol L−1, was 0.92. With the 100ppm sweep gas, this was ratio was 1.23
for both lungs. At the lowest end of NO sweep gas concentration tested (10ppm), this
ratio was diﬀerent for each lung type. We calculated 3.75 for the Capiox RX25 and
0.89 for the Biolung. The ratio was exceptionally higher for the Capiox lung with the
10ppm NO/N2 sweep gas probably because the fluid used was below room tempera-
ture and thus increased the solubility of the NO. However, these ratios are generation
close to 1, indicating agreement of our in vitro work with existing literature.
Based on our in vitro studies, we are able to provide a diﬀerent interpretation of
some of the NO sweep gas results reported in literature. Although diﬀerent oxygena-
tors were used in works cited, most of them had surface areas (1.3 -1.9 m2) comparable
to that of the Biolung (1.7 m2) and Capiox RX25’s (2.5 m2). Therefore, the flux levels
per NO sweep gas blend used in other studies should follow our predicted time-zero
NO flux values. Another similarity that can be drawn between our oxygenators and
those used in literature is their gas-exchange material. The gas exchange material of
the Capiox RX25 is polypropylene and polymethyl pentene for the Biolung. Those
in literature comprise of but not limited to polypropylene and polymethyl pentene.
These similarities in material and surface area of the oxygenators perhaps can allow
for the use of our time-zero NO flux values to justify why inhibition of platelet activa-
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tion was insignificant in studies where 40ppm [5], 100ppm [6], and 500/1000ppm [8]
was used. Their NO flux levels were too low to significantly inhibit platelet activation.
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CHAPTER VII
CONTRIBUTIONS, LIMITATIONS AND
FUTURE WORKS, AND CONCLUSION
7.1 Contributions
The presented study has many contributions to the knowledge base on the syn-
thesis, fabrication, characterization, and non-thrombogenic evaluation of nitric oxide
releasing and generating surfaces. In summary:
Synthesis and characterization of nitric oxide-generating silicone
for use as a blood-contacting biomaterial:
1. To the best of the author’s knowledge, the characterization of Cu-mediated
NO generation from S-nitrosothiols on silicone polymer is the most advanced
and complete characterization, which considers polymer surface microstructure,
eﬀect of wt% Cu on surface expression of Cu and NO flux and gives an insight
into blood coagulation on Cu-mediated NO-generation silicone.
2. Micro and nano Cu particles coalesce to form dendritic structures inside the
polymer membrane and on the surface of the polymer. The expression of the
dendrites on the surface is necessary for NO generation from S-nitrosothiols
especially in hydrophobic polymers.
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3. NO flux bears linear relationships with wt% Cu range tested and clotting time
of whole blood.
4. This study provides many interesting conclusions regarding NO generation
through Cu-mediated S-nitrosothiol decomposition: At 10 wt%, the clotting
time is 4.24 times greater than with pure silicone, additional Cu will have di-
minishing returns, as the surface concentration of copper does not increase
markedly with increasing wt% in this range.
Nitric oxide-generating silicone application to hollow fiber
oxygenator technology: development and biocompatibility evaluation:
1. To the best of the author’s knowledge, the developed Cu-mediated NO-generating
hollow silicone fiber oxygenator is the first and most complete study regard-
ing the application of NO-generation coating to a clinical device and its non-
thrombogenic evaluation.
2. Many interesting findings important for assessing the applicability of this novel
approach to clinical oxygenators is made. They include, surface morphology
of the silicone hollow fiber, NO flux levels from fibers, flow pattern of NO-
generating oxygenator, non-thrombogenic evaluation by device resistance, flows,
platelet consumption and fibrinogen consumption.
3. This work also provides important information on Cu leaching into plasma and
thus an assessment of the toxic eﬀects of leached Cu levels.
Non-thrombogenic characterization of extruded nitric oxide-releasing
silicone catheters:
1. To the best of the author’s knowledge, silicone catheters extruded with chemical
species that allow post-extrusion NO charging to create a nitric oxide-releasing
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(≥ 2 x 10−10 mol min−1cm−2) catheters is the first and foremost of its kind.
This study fully describes the eﬀect of catheter structure, wall chemistry, and
post NO-charging storage condition on NO release levels and duration of sil-
icone catheters. Their non-thrombogenicity evaluation and outcomes are also
presented.
2. The extrusion-over-mandrel process is, for the first time, applied to the fabri-
cation of nitric oxide releasing catheters. The process is adequate for the man-
ufacturing of 12 gauge OD catheters implantable in the right and left internal
jugular veins of adult rabbits for non-thrombogenicity evaluation.
3. In the synthesis and fabrication process used, it was found that the NO releas-
ing catheter produced endothelial NO flux levels, the flux level is a function of
DACA-6 content and is aﬀected by anionic agents and catheter storage condi-
tions.
4. The level of NO flux released by the catheters is adequate for significant reduc-
tion of catheter occlusion in a 4h non-thrombogenicity testing.
Nitric oxide in sweep gas for local clot inhibition in oxygenators:
1. To the best of the author’s knowledge, nitric oxide in sweep gas for the reduction
of blood coagulation in oxygenators has been studied for over 15 years. However,
characterization of the gas’s flux level in oxygenators has never been studied
hence making it impossible to settle on what sweep gas NO concentration can
produce endothelial NO flux level or flux levels eﬀective for significantly reducing
blood coagulation in oxygenators without systemic anticoagulation.
2. An experimental procedure for quantifying NO flux at the surface of gas ex-
change fibers of commercial oxygenators for diﬀerent sweep gas NO concentra-
tions is described.
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3. NO flux levels in the Biolung and Capiox RX25 oxygenators using 10, 100 and
1000 ppm sweep gas NO concentrations is presented. It is found that between
a 1000 and 2000 ppm sweep gas NO concentrations will produce endothelial
levels of NO flux on those oxygenators. This implies that previous studies
examining NO in sweep gas were largely underpowered in terms of sweep gas
NO concentration used.
7.2 Limitations and Future Works
This study, however, bears some limitations due to diﬀerences in simulated in
vivo environment and the actual in vivo milieu. Those limitations, along with related
suggestions for each study, can be largely summarized as follows:
1. In the nitric oxide sweep gas work water, instead of blood, was used for studying
NO flux on the gas exchange membranes of oxygenators as no reliable technique
currently exists for measuring dissolved NO in blood. Blood has far more NO
scavenging species that may increase the transfer of NO across gas exchange
membranes and thus, perhaps, a lesser sweep gas NO concentration may produce
endothelial NO flux levels with blood flow. In clinical practice oxygen is bled
into oxygenators to oxygenate flowing blood. When NO is also swept into
the artificial lung, it can be oxidized into nitrite by oxygen. Hence the NO
concentration inhibiting platelet activation at the polymer/blood interface may
be diﬀerent from that provided by the NO sweep gas.
2. The NO release duration and in vivo non-thrombogenicity of the nitric oxide-
releasing catheters were studied and evaluated for 24h and 4h respectively. Clin-
ical need requires these catheters to remain patent for weeks to months, and
therefore a longer-term study is required. The duration of NO release should be
studied in order to extend their patency up to 30 d and beyond. To get there,
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diﬀerent NO immobilizing compounds and anionic sites must be investigated.
3. The NO-generating silicone for blood-contacting coating study showed many
positive results. However, the study is limited by the short periods of blood
biomaterial contact and the relatively static setting. The eﬀectiveness of the
Cu/Si PMC on coagulation for periods of hours to days under appropriate
blood flows must be studied. Cu leaching from the surface of the coating into
the bulk fluid was not addressed. These concerns are however addressed in the
NO-generating membrane lung study.
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7.3 Conclusion
The research conducted herein investigated the use of nitric oxide as a means
of inhibiting clot formation at the surfaces of blood-contacting artificial materials.
Diﬀerent surfaces were functionalized with NO production using three methods that
involved chemical and physical modifications of materials. The chemical methods
included: (1) NO generation at the surface of artificial materials via the decomposition
of NO donors using Cu catalysts and (2) NO release from surfaces after incorporation
of NO donors inside their bulk. And by the physical method, artificial materials were
functionalized to produce NO after flowing NO gas over their surfaces.
For long-term use of artificial lungs, both physical and chemical means of NO
functionalization may help inhibit clot formation. The catalytic means of NO pro-
duction from using Cu catalysts and NO donors allows for continuous NO generation
as long as the physical interaction between the catalyst and the NO donor remains
unhindered. The ability of this method to generate NO continuously makes it a good
candidate for applications requiring blood-contacting devices to remain functional for
months. The hollow thin-walled gas exchange fibers of artificial lungs is a good fit for
this method of NO production. It interfaces with blood only at their outer surface so
NO donors infused into flowing blood can drive a continuous generation of NO from
these fibers. NO supplementation into sweep gas may prove even more eﬃcient for
long-term use of artificial lungs. It does not involve modification of materials using
complex and expensive chemical formulations, and the gas is also commercially avail-
able at several concentrations. All of these methods, however do have one potential
underlining drawback of the formation of metHemoglobin when they lead to high NO
flux production. In addition, the use of Cu as a catalyst for NO generation can lead
to Cu toxicity. NO generation from this method may also decrease due to protein
adsorption and Cu leaching from fibers.
In short-term (up to 4h) respiratory support by ECMO, AVCO2R, and CPB, their
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artificial lungs’ gas exchange fibers and extracorporeal circulatory surfaces could be
modified to incorporate NO releasing materials for a controlled release. It should
be noted that NO flux from such thin walls (up to 50 µm) may be limited to near
low-end endothelial NO flux levels. During hemodialysis, dialysis membranes filter
blood anywhere up to 4 h at a time, and therefore NO releasing coatings on their
membranes is a more practical approach for controlling clot formation.
Catheters, on the other hand, interact with blood both on their lumen and on their
outer surfaces. NO production is thus required on both sides of their walls although
more so on their outer surfaces where blood continuously flows. The incorporation of
NO releasing materials in their walls for controlled release from both surfaces appear
to be a more eﬃcient method for functionalizing catheters.
Ultimately, the selection of a surface functionalization with NO method for a de-
vice will depend on the intended duration of use, how the device works, and the
structure and size of the blood-contacting surface. Long term use of blood-contacting
devices require methods able to sustain long term NO production, gas exchange de-
vices is a natural fit for NO supplementation, and small diameter pediatric catheters
is a good fit for NO release material incorporation.
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